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PROPHYLACTIC CRANIAL IRRADIATION REDUCES THE INCIDENCE OF BRAIN
METASTASIS IN A MOUSE MODEL OF METASTATIC BREAST CANCER
Daniel Smith
Advisory Professor: Wendy Woodward, M.D., Ph.D.
Prophylactic cranial irradiation (PCI) is a preventative whole-brain irradiation technique used to
reduce the incidence of brain metastasis and improve overall survival in select patients with
small cell lung cancer and acute lymphoblastic leukemia. A population of breast cancer patients
– stage IV, HER2+ or triple-negative – has emerged as having a high risk of developing brain
metastases.

Because only 10-20% of breast cancer patients diagnosed with brain metastases

survive longer than one year, in this high-risk population the benefit of PCI – potential for
reduced incidence of brain metastasis and improved overall survival – may outweigh the risks –
radiation toxicity. The objective of this thesis was to determine if a PCI dose could reduce the
incidence of brain metastasis.
A mouse model of metastatic, HER2+ inflammatory breast cancer was used to evaluate
the effect of 4-Gy whole-brain irradiation on the incidence of brain metastasis.

Mice were

irradiated at different time points and were sacrificed at either four or eight weeks after cell
injection.

The principal endpoints of incidence of brain metastasis, the number of brain

metastases per mouse, and the metastatic burden were all significantly decreased in the PCI arm,
but unaffected when the whole-brain irradiation was delayed.
To expand on the experimental findings, a computational model of subclinical breast
cancer dose-response was developed.
conducting a limiting dilution assay.

After optimization, the model was validated by

By adjusting the model inputs of radiation dose and time

of irradiation, a time course of the incidence of brain metastasis and related endpoints was
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mapped.

The model predicts that delaying treatment introduces a dose threshold below which

the incidence is unchanged, a finding that is consistent with the experimental data.
This work highlights the importance of the timing of radiation therapy as it relates to
the treatment of subclinical disease, specifically breast cancer micrometastases in the brain. The
principal findings have the potential to impact how breast cancer patients at high risk of
developing brain metastases are managed in the clinic, and PCI clinical trials in these patients
could be considered.

vi

TABLE OF CONTENTS
Approval Sheet ......................................................................................................................................i
Title Page...............................................................................................................................................ii
Acknowledgements ................................................................................................................................iii
Abstract..................................................................................................................................................v
Table of Contents...................................................................................................................................vii
List of Figures ........................................................................................................................................ix
List of Tables .........................................................................................................................................xi
Abbreviations .........................................................................................................................................xii

Chapter 1: Introduction ........................................................................................................................1
Section I: Breast Cancer ........................................................................................................................1
Section II: Brain Metastasis ...................................................................................................................7
Section III: Prophylactic Cranial Irradiation..........................................................................................20
Section IV: Scope of Dissertation ..........................................................................................................30

Chapter 2: Prophylactic Cranial Irradiation Reduces Breast Cancer Brain Metastasis in Mice........32
Section I: Introduction............................................................................................................................32
Section II: Methodology.........................................................................................................................36
Section III: Results .................................................................................................................................41
Section IV: Conclusions.........................................................................................................................58

vii

Chapter 3: Radiobiological Modeling of Subclinical Breast Cancer Dose-Response..........................64
Section I: Introduction............................................................................................................................64
Section II: Methodology.........................................................................................................................67
Section III: Results .................................................................................................................................75
Section IV: Conclusions.........................................................................................................................94

Chapter 4: General Discussion .............................................................................................................100

Bibliography...........................................................................................................................................106
Appendix I: Survivin & Radiation Response ........................................................................................125
Appendix II: Molecular Imaging of Hedgehog Signaling .....................................................................126
Vita ........................................................................................................................................................127

viii

LIST OF FIGURES
Figure
1

Metastatic Spread from Breast and to Brain………………………………………

13

2

Mouse Model of Metastatic Inflammatory Breast Cancer………………………...

15

3

Treatment Guidelines for Patients with Brain Metastases………………………...

19

4

Stratification of Patients at Risk of Developing Brain Metastases………………..

26

5

Design of Prophylactic Cranial Irradiation Experiment…………………………...

39

6

Setup for Irradiation of Mice………………………………………………………

40

7

Representative Images of Brain and Lung Metastases at Four-Week Endpoint…..

44

8

Number of Brain Metastases per Mouse at Four-Week Endpoint………………...

45

9

Weight of Mice Sacrificed at Four-Week Endpoint………………………………

47

10

Representative Images of Brain and Lung Metastases at Eight-Week Endpoint….

52

11

Number of Brain Metastases per Mouse at Eight-Week Endpoint………………..

53

12

Brain Metastases Burden per Mouse at Eight-Week Endpoint……………………

54

13

Weight of Mice Sacrificed at Eight-Week Endpoint……………………………...

57

14

Overview of Development, Execution, and Evaluation of Model………………...

67

15

Gaussian Fit of Number of Metastases per Mouse at Four-Week Endpoint………

75

16

Gaussian Fit of Number of Metastases per Mouse at Eight-Week Endpoint……..

76

17

Log-Normal Fit of Experimental Volumes………………………………………..

78

18

Metastases Growth Curves………………………………………………………...

79

19

Optimized Input Distributions……………………………………………………..

82

20

Comparison of Experimental Gaussian Fit to Model Output……………………...

83

21

Validation of Computational Model………………………………………………

84

ix

22

Incidence of Brain Metastasis at Eight-Week Endpoint…………………………..

86

23

Number of Brain Metastases per Mouse at Eight-Week Endpoint………………..

87

24

Tumor Burden at Eight-Week Endpoint…………………………………………..

88

25

Reduction in Incidence compared to Non-Irradiated Control……………………..

90

26

Reduction in Number of Metastases compared to Non-Irradiated Control……….

91

27

Reduction in Incidence compared to Non-Irradiated Control……………………..

92

28

Assumptions about Hypoxia in Model…………………………………………….

93

x

LIST OF TABLES
Table
1

Breast Cancer Subtypes……………………………………………………………

3

2

Clinical Data for Prophylactic Cranial Irradiation in SCLC and ALL Patients……

24

3

Presence of Brain Metastases at Four-Week Endpoint…………………………….

43

4

Presence of Lung Metastases at Four-Week Endpoint…………………………………….

46

5

Presence of Any Metastases at Four-Week Endpoint……………………………...

46

6

Association between Brain and Lung Metastases at Four-Week Endpoint………..

46

7

Presence of Brain Metastases at Eight-Week Endpoint……………………………

50

8

Presence of Brain Metastases in Overall Study……………………………………

55

9

Presence of Lung Metastases at Four-Week Endpoint…………………………….

55

10

Presence of Any Metastases at Four-Week Endpoint……………………………...

56

11

Association between Brain and Lung Metastases at Eight-Week Endpoint……….

56

12

Association between Brain and Lung Metastases in Overall Study……………….

56

13

Comparison between model predictions and experimental results………………...

96

xi

ABBREVIATIONS

Abbreviation
13

Full Description

C

131

Carbon-13

I

Iodine-131

AI

Aromatase Inhibitors

ALL

Acute Lymphoblastic Leukemia

BBB

Blood Brain Barrier

BMFS

Brain Metastasis Free Survival

BMT

Autologous Bone Marrow Transplantation

CNS

Central Nervous System

CSCs

Cancer Stem Cells

CSF

Cerebrospinal Fluid

CT

Computed Tomography

DSBs

Double Strand Breaks

EGFR

Epidermal Growth Factor Receptor

EMT

Epithelial-Mesenchymal Transition

ER

Estrogen Receptor

GFP

Green Fluorescent Protein

Gy

Gray

HER2

Human Epidermal Growth Factor Receptor 2

IBC

Inflammatory Breast Cancer

IMRT

Intensity-Modulated Radiation Therapy

IR

Ionizing Radiation

IV

Intravenous
xii

LABC

Locally Advanced Breast Cancer

mBC

Metastatic Breast Cancer

MET

Mesenchymal-Epithelial Transition

miR

Micro RNA

MRI

Magnetic Resonance Imaging

NCF

Neurocognitive Function

NSCLC

Non-Small Cell Lung Cancer

OS

Overall Survival

PCI

Prophylactic Cranial Irradiation

PET

Positron Emission Tomography

PFS

Progression-Free Survival

PR

Progesterone Receptor

RFS

Relapse-Free Survival

SCLC

Small Cell Lung Cancer

SERMs

Selective Estrogen Receptor Modulators

SSBs

Single Strand Breaks

SRS

Stereotactic Radiosurgery

STAT3

Signal Transducer and Activator of Transcription 3

TGFβ

Transforming Growth Factor Beta

TNBC

Triple-Negative Breast Cancer

TNM

Tumor Node Metastasis Staging System

VEGF

Vascular Endothelial Growth Factor

WBRT

Whole-Brain Radiation Therapy

xiii

CHAPTER 1: INTRODUCTION
SECTION I. BREAST CANCER
Breast cancer is the most common malignancy and the second leading cause of cancer death
among females in the United States, who have an approximately 12% lifetime risk of
developing the disease. It was estimated that 232,340 new cases of invasive breast cancer were
diagnosed in the United States in 2013, with 39,620 fatalities [1].

According to the National

Cancer Institute, the five-year survival rate for breast cancer patients ranges from 99% for
localized disease to approximately 24% for advanced disease at the time of diagnosis [2].

A. Molecular Subtypes
Breast cancer is increasingly considered a group of diseases distinguished by molecular or
receptor subtypes, clinical behaviors, and treatment response.

Breast cancers are commonly

stratified into receptor subtypes based on the presence or absence of the estrogen receptors (ER),
progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) [3]. For
the purposes of this report, I will group breast cancers into three unique subtypes: luminal,
HER2-enriched, and basal-like.
The majority of breast cancers are of the luminal subtype, which are estrogen receptorpositive (ER+) and/or progesterone receptor-positive (PR+).

Patients with luminal breast

cancers tend to have a better prognosis than other breast cancer patients, due in large part to the
slow-growing, less aggressive nature of these tumors.

The luminal subtype is further subdivided

into luminal A and luminal B: luminal B breast cancers are HER2-enriched and these patients
have a worse prognosis than luminal A breast cancer patients. In patients with luminal A breast
cancers, expression of the hormone receptors ER and/or PR is predictive of a favorable response
to hormonal therapies such as tamoxifen.
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Approximately 15-20% percent of breast tumors overexpress human epidermal growth
factor receptor 2, but do not express the hormone receptors, ER and PR [3]. HER2-enriched
(HER2+) breast cancers tend to grow faster and spread more aggressively than luminal tumors
and, consequently, these patients have worse short-term prognosis.

In recent years, targeted

therapies for HER2+ breast cancers, such as trastuzumab and lapatinib, have improved the
overall prognosis for these patients.
Ten to twenty percent of breast cancers patients have basal-like breast cancer, and most
of these are referred to as triple-negative breast cancer, as they are ER-, PR-, and HER2. Like
HER2+ breast cancers, these tumors are normally very aggressive and the patients have poor
prognosis; moreover, due to the triple-negative status, there is a dearth of treatment options. For
simplicity, I will refer to this subset of breast cancers as triple-negative breast cancer
throughout the report.

B. Inflammatory Breast Cancer
Inflammatory breast cancer (IBC) – a variant of locally advanced breast cancer (LABC) –
accounts for approximately 2.5% of all breast cancer cases. It is characterized by aggressive
behavior, rapid progression, breast enlargement, peau d’orange appearance, erythema, skin
thickening, and dermal lymphatic invasion.

Due in part to its rarity, IBC is commonly

misdiagnosed as mastitis or generalized dermatitis [4].

Currently, IBC is primarily a clinical

diagnosis, according to the American Joint Committee on Cancer (AJCC) staging manual [5], as
no gene or molecular signatures have been identified that clearly distinguish IBC from other
breast cancers [6, 7].
IBC may possess any combination of the hormone receptors and HER2, but they most
often fall into the HER+ or triple-negative breast cancer clusters.

In fact, HER2 has been

reported to be overexpressed with greater frequency in IBC (36-60%) compared to non-IBC [8].
2

3

ER+, PR+, HER2+
ER+, PR+, HER2ER-, PR-, HER2+
ER-, PR-, HER2-

Luminal A

Luminal B

HER2-enriched

Basal-like/Triple-negative

EGFR inhibitors

Trastuzumab, Lapatinib

Chemotherapy

Hormonal therapy

Common Treatments

(-): low or undetectable

10-20%

15-20%

20-25%

25-35%

Prevalence

Poor

Poor

Poor

Good

Prognosis

Table 1: Major Molecular Subtypes in Breast Cancer. The principal subytpes in breast cancer are the luminal
tumors, charaterized by their expression of the hormone (estrogen and progesterone) receptors; HER2-enriched, breast
cancers that overexpress human epidermal growth factor receptor 2, but do not express hormone receptors at high
levels; and basal or triple-negative breast cancer, which overexpresses neither the hormone receptors nor HER2.
Patients with luminal tumors fare well compared to patients with the more aggressive HER2 and triple-negative breast
cancers.

Adapted from these publications:
1) Carey L, et al . Journal of the American Medical Association 2006, 295(21): 2492-2502.
2) Perou C, et al. Nature 2000, 406: 747-52.

(+): overexpressed

Expression Profile

Subtype

Patients with IBC have a worse prognosis – a 35-40% five-year survival – than other LABC
patients because of the high incidence of distant metastasis (roughly 70%) [9] and because of a
higher incidence of recurrence after multidisciplinary treatment [10].

Similarly, the median

survival for IBC patients is 2.9 years compared to 6.4 years for LABC patients [11].

C. Breast Cancer Treatment Options
Treatment options for patients with breast cancer include surgery, radiation therapy, and
systemic therapies such as chemotherapy, hormone therapy, and/or targeted therapy.
patients with breast cancer will undergo

Most

surgery (either breast-conserving surgery or

mastectomy [entire breast removal]), both to remove the cancer from the breast tissue and also
to determine the stage of the disease. Surgery to remove the cancerous tissue from the breast is
normally accompanied by removal of axillary lymph nodes (or a sentinel lymph node biopsy
[12]) to help determine the spread of disease beyond the breast and to inform the course of
subsequent therapy. Surgery is typically combined with other treatments.
Radiation

HIGHLIGHTS
 Breast cancers are grouped in molecular subtypes: luminal, HER2enriched (HER2+), and triple-negative (estrogen and progesterone
receptor-negative, HER-)
 Patients with HER2-enriched and triple-negative breast cancers
(TNBC) have the worst prognosis
 Inflammatory breast cancer is an aggressive form of breast cancer
distinguished by its rapid progression and appearance; most cases
fall into the HER2-enriched or TNBC subtypes
 Most breast cancer patients will be treated with surgery and
radiation therapy, while systemic therapy is the primary treatment
option for patients with metastatic breast cancer
 The monoclonal antibody trastuzumab is a common systemic agent
that targets the HER2 protein and reduces recurrence in HER2enriched breast cancer patients

 Five-year survival rates range from 99% for localized disease to
25% for advanced disease

either

therapy,

external-beam

radiation

therapy

or

brachytherapy, is used as an
anti-cancer treatment in the
majority
patients.
has

of

breast

cancer

Radiation therapy

several applications in

breast

cancer

patients,

including shrinking previously inoperable tumors prior to surgery, destroying cancer cells in the
breast after a potentially curative surgery, or as a palliative in patients with advanced disease.
4

Radiation therapy is given after breast-conserving surgery to reduce the risk of recurrence by
50% and the risk of breast cancer death by approximately 20% [13]. These patients who receive
the combined breast-conserving surgery plus radiation regimen have the same expected longterm survival as patients who undergo a mastectomy [14].
Systemic therapies, administered orally or intravenously, affect all parts of the body and
can be given to breast cancer patients either before surgery – neoadjuvant therapy – or after the
surgery – known as adjuvant therapy.

Neoadjuvant systemic therapies are often used, like

radiation, to shrink the tumor enough to enable its surgical removal or to allow for less extensive
surgery.

Adjuvant therapies are primarily used to kill residual tumors cells or cells that have

migrated to other parts of the body. For women with metastatic breast cancer, systemic therapy
is generally the principal treatment as the patients may not benefit from surgery or radiation.
The most common systemic treatment is chemotherapy, a class of agents that are
designed to target rapidly dividing cancer cells.

However, chemotherapy has very well-known

side effects because rapid cell division is not a characteristic unique to cancer cells.
Chemotherapy

drugs

–

alkylating

agents,

antimetabolites,

anti-microtubule

agents,

topoisomerase inhibitors, and anthracyclines – prevent mitosis by damaging DNA and inhibiting
the cell division process.

In most cases, drug combinations are more effective than

monotherapies in the treatment of breast cancer [15].

Triple-negative and HER2+ breast

cancers tend to be more sensitive to chemotherapy than their luminal counterparts [16].
Hormone therapy, a different class of systemic agents, is often given to breast cancer
patients whose tumors are ER+ or PR+. Estrogen receptor and progesterone receptor transmit
the signals from the steroid hormones estrogen and progesterone, respectively, promoting the
growth of luminal breast cancers. There are three major hormonal therapies: selective estrogen
receptor modulators (SERM), ovarian ablation, and aromatase inhibitors (AI). SERM, such as
tamoxifen and raloxifene, prevent estrogen from binding to the estrogen receptor, and it has
5

been shown that they reduce the rate of breast cancer recurrence and mortality [17]. Ovarian
ablation involves either surgical removal of the ovaries – the major source of estrogen prior to
menopause – or with drugs known as luteinizing hormone-releasing hormone analogs [1].
Finally, AI such as letrozole and anastrozole act against aromatase, the enzyme that synthesizes
estrogen, and demonstrate a clear benefit in postmenopausal women [18].
Therapies targeted at HER2 – the protein that is important in the development and
progression of HER2+ breast cancers – have improved the prognosis for patients with this breast
cancer subtype.

Most notably, the humanized monoclonal antibody trastuzumab directly targets

the HER2 protein, and it has been shown that combining trastuzumab with chemotherapy
reduces the risk of recurrence by 52% and death by 33%, compared to chemotherapy alone [19].
Trastuzumab was approved by the U.S. Food and Drug Administration in 2006 for all HER2+
breast cancers. Other systemic treatments have also exhibited benefit for HER2+ breast cancer
patients, such as pertuzumab and lapatinib.
Most patients with inflammatory breast cancer present with locoregional disease, and
there is a high probability of residual disease if surgery is used upfront. It is recommended that
IBC patients first receive a primary systemic regimen consisting of an anthracycline and a
taxane, with the goal of shrinking the tumor to allow for mastectomy and axillary lymph node
dissection [20].

Similar to non-IBC patients, the addition of trastuzumab to systemic

chemotherapy is associated with higher pathologic complete response in HER2+ inflammatory
breast cancer patients [21], and it is recommended that all women with ER- or PR-positive
inflammatory breast cancer receive either tamoxifen or an aromatase inhibitor [20].

All IBC

patients who undergo a mastectomy are recommended to receive radiation therapy.

Finally,

IBC patients with metastatic disease should undergo systemic therapy first and then local
therapy (radiation and/or surgery) for palliative purposes [4].
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While multimodality therapies have improved the prognosis for breast cancer patients,
there is a need for novel therapeutic approaches to improve the outcomes of patients whose
cancer metastasizes to the lungs, liver, bone, and, most relevant to this investigation, to the
brain.

SECTION II. BRAIN METASTASIS
Cancer metastasis is the process by which malignant cells spread from the primary tumor to
unconnected organs.

Despite major advances in diagnosis, surgical techniques, and local and

systemic treatments, most deaths due to cancer result from the progression of metastases that are
resistant to conventional therapies [22].

Metastasis is the primary clinical challenge due to its

unpredictability and the adverse impact it has on cancer patients, and therefore the development
of improved therapies for metastasis is one of the primary goals of cancer research.

A. The Biology of Metastasis
Metastases arise from a selected subpopulation within the biologically heterogeneous primary
tumor [23].

Because of the many steps required to form metastases, fully metastatic cells are

rare clones in the tumor; less than 0.01% of the cancer cells entering the circulation in animal
models develop into metastases [24, 25].
The metastatic cascade consists of a series of sequential and interrelated steps, beginning
when tumor cells invade the host stroma, which contains thin-walled venules and lymphatic
channels [26].

This is possible only after the tumor cells undergo the epithelial-mesenchymal

transition (EMT), through which they shed many of their epithelial phenotypes and acquire the
transcriptional program characteristic of mesenchymal cells. The EMT process affects not only
the shape and motility of tumor cells, but also leads to major alterations in their gene expression
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profiles: Most notably, expression of E-cadherin, a protein that enables epithelial cells to adhere
to one another, is repressed [27].
After the tumor cells have moved into the lumina of blood and lymphatic vessels (known
as intravasation), they detach from the extracellular matrix in the host tissue and can circulate in
both the hematologic and lymphatic vasculature as aggregates. The rare cells that are able to
survive the actively hostile environment of the circulation then arrest in distal capillary beds
[28].
To form metastases, cancer cells must escape from the vasculature and penetrate into the
surrounding tissue – a process known as extravasation – and they are able to do so via multiple
mechanisms [26].

Tumor cells could either migrate between adjacent endothelial cells across

intercellular junctions or through an endothelial cell that lines the vessel lumen [29]; for
example, certain cancer cells secrete acid that stimulates endothelial cell retraction [30], while
others can proliferate and form a mass within the lumen that exerts enough pressure on the
vessel well to cause a rupture [31].
Last, the tumor cells proliferate within the newly-accessed organ parenchyma and
establish their own vasculature supply, resulting in a metastatic focus [28].
The outcome of the metastatic process is in large part determined by complex
interactions between metastatic cells and the host tissue [26].

Within the metastatic cascade,

studies indicate that the rate-limiting step is the initiation of cell growth in the secondary organ,
or colonization [32]: some tumors cells remain dormant in secondary organs [33], while in other
tumors the absence of angiogenesis places a ceiling on tumor growth [34].

In general, the

quantity of micrometastases in the body greatly outnumbers those that will grow large enough
for clinical detection.

These micrometastases could be widely disseminated throughout the

tissues of a cancer patient and, because of their potential to form life-threatening masses,
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targeting them before they become full-fledged metastases may in certain cases be an effective
strategy.
Over a century ago, Stephen Paget suggested that metastasis is not a random process;
rather, some tumor cells (the “seed”) are specialized to grow preferentially in certain organs (the
“soil”), and that metastasis was possible only when the “seed” grew in the appropriate “soil”,
analogous to the dispersal of plant seeds [35].

In the past half century, studies have

demonstrated that the microenvironment plays a crucial role in regulating metastatic growth,
supporting the “seed and soil” hypothesis [36].

Others have declared that the principal factor

that dictates metastatic spread is the anatomy of the hematologic and lymphatic drainage from
the primary tumor site [27].

While these hypotheses are not mutually exclusive, there is

consensus that certain primary tumor types demonstrate an organ-specific pattern of
dissemination, and the brain is one of the most common sites for the development of treatmentresistant metastases.

B. Brain Metastasis
Central nervous system (CNS) metastases account for the majority of malignant brain tumors,
with an estimated annual incidence of 150,000-170,000 cases [37].

In the course of their

disease, approximately 8-10% of adults with cancer will develop symptomatic brain metastases
[38, 39] and, in up to half of these patients, the cause of death can be attributed to progression of
brain metastasis [40]. Most brain metastases arise from the lung (40-50%), from melanoma (520%), or from the breast (15-25%) [38, 39]. Brain metastases tend to occur late in the course of
a patient’s cancer, when the primary tumor has already spread extensively to other organs; when
the primary tumor was successfully treated, brain metastases may actually be the result of
secondary metastasis [37].

Metastatic brain tumors are expected to become more prevalent, as

more effective treatments of systemic disease lead to longer patient survival after primary
9

cancer diagnosis.

In addition, the frequency of diagnosis is also likely to increase due to

improvements in advanced imaging modalities and earlier detection [41].
Cognitive decline has been observed in almost two-thirds of patients with brain
metastases [42, 43].

These lesions are often specified by symptoms, including headaches,

seizures, loss of motor or sensory function, cranial neuropathy (abnormal function of a cranial
nerve), and cognitive impairment – and validated with advanced imaging modalities, where
lesions of a few millimeters in size are detectable [44].
In

HIGHLIGHTS
 Metastasis is an inefficient, multi-step process that involves tumor
cells accessing the systemic circulation, exiting the circulation at
distant sites, and colonizing the new host organ

 Brain metastases account for most malignant brain tumors
 Ten percent of cancer patients will develop symptomatic brain
metastases during their disease, most of which arise from the lung,
the breast, or from melanoma

process,
arrest
must

the
tumor

in

metastatic
cells

brain

that

capillaries

extravasate

into

the

 Cognitive decline is observed in two-thirds of patients with brain
metastases

brain parenchyma to form a

 Autopsy reports have identified micrometastases in the brain below
the threshold for clinical detection, and brain metastases have
formed several years after the cure of the primary cancer in some
patients, suggesting a dormant cancer cell population

clinically
metastatic

focus;

 Treating this undetectable dormant cell population as a prophylactic
is an attractive strategy to reduce the incidence of brain metastases

the

may

 Astrocytes and microglia in the brain may promote the colonization
step of metastasis

proliferate while still in the

cells

detectable
however,
begin

capillary bed [45].

to

Eighty

percent of brain metastases are detected in the cerebral hemispheres, 15% in the cerebellum, and
5% in the brainstem, closely mirroring the tissue volume and blood flow in the brain [37].
There is evidence that endothelial cells lining the brain vasculature actually promote metastatic
cell growth and invasion [46, 47]. The blood-brain barrier (BBB) – the permeability barrier that
separates the systemic circulation from extracellular fluid in the brain – does not inhibit tumor
cell extravasation, although it does have major implications for systemic therapies [37].
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If the “soil” is not fertile, tumor cells that leave the brain vasculature and enter the
parenchyma may not grow, but instead die or remain dormant for years [24]; one label-retention
study found that for every overt metastasis formed in the mouse brain, three disseminated tumor
cells remained dormant [48]. Also, there is evidence of brain metastases developing in patients
several years after the cure of the primary cancer: surgery and chemotherapy may have
eradicated all extracranial disease, with the BBB protecting dormant tumor cells in the brain,
providing a substantial pool of cancer cells to potentially lead to further metastases. This is one
of the proposed reasons prophylactic whole-brain radiation therapy treatments have been
successful in small-cell lung cancer patients [49], to be discussed in depth later.
After infiltration into the brain parenchyma, the tumor cells encounter several host cells,
most notably the microglia and astrocytes, and a microenvironment that is conducive to tumor
growth and treatment resistance.

In experimental systems, activation of both microglia – glial

cells that are the principal macrophages in the brain – and astrocytes – brain cells that form a
physical and metabolic support system for nerves – has been well-documented [50-52].
Additional studies have suggested that microglia can enhance the invasion and colonization of
disseminated tumor cells [53], and that astrocytes may both protect brain metastases from
toxicity induced by chemotherapy [54, 55] and promote tumor cell proliferation.
Tumor growth is highly dependent on the establishment of an adequate blood supply,
and tumors are able to recruit blood vessels through a variety of mechanisms.

During the

colonization process, vascular changes in the brain lead to lower vessel density as well as more
dilated and tortuous vasculature compared to the normal brain [56]. The production of vascular
endothelial growth factor (VEGF) seems to be necessary, but not sufficient, for cancer cells to
proliferate in the brain [57]; however, anti-angiogenic therapies have shown mixed results in
preclinical studies.

Other prominent genetic alterations play a role in brain metastases, many of

which may be specific to primary cancers, such as those of the breast.
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C. Brain Metastasis in Breast Cancer Patients
Breast cancer is the second most common cause of brain metastasis, after lung cancer.

Brain

metastases are diagnosed roughly three years after the initial diagnosis of breast cancer [58] and,
in most cases, after the appearance of systemic metastases in the bone, lung, and/or liver [59].
The prognosis is poor for all breast cancer patients who develop brain metastases, with reported
median survival after brain metastasis diagnosis of 3.7, 9, and 15 months for triple-negative,
HER2+, and luminal subtypes, respectively [60-62].
than 20%.

Historically, the one-year survival is less

Notably, due to improvements in systemic therapy, control of extracranial disease

may no longer be the limiting factor in survival among breast cancer patients with brain
metastases [63].
The risk of brain metastases is low – approximately 5% – when considering the entire
breast cancer patient population; however, 10-16% of patients with stage IV breast cancer
develop metastases [64, 65], while many brain lesions are asymptomatic and go unidentified
until autopsy in 20-40% of advanced stage patients [66]. Broken down further, it is estimated
that 25-35% of HER2+ stage IV breast cancer patients and 40-45% of TNBC stage IV patients
will develop brain metastases [67, 68]. Because these stage IV, HER2+ and TNBC patients not
only have the highest risk of developing brain metastases but also of succumbing to them,
prevention is an attractive option. Risk factors and prevention of breast cancer brain metastasis
will be explored thoroughly in Section III.
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Figure 1: Metastatic Spread from Breast and to Brain. The principal organs to which the
breast metastasizes are the lungs, the liver, bone, and the brain. Typically, breast cancer brain
metastasis will occur after the primary breast cancer has spread to other organs throughout the
body. The most common tumors that metastasize to the brain are lung cancer (40-50%), breast
cancer (15-25%), and melanoma (5-20%). Interestingly, secondary metastases have been
observed in the brain, notably from primary breast tumors via lung metastases.
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Several genetic alterations are involved in the formation of brain metastases originating
from breast cancer [41, 69], most of which are beyond the scope of this review. However,
HER2, the member of the epidermal growth factor receptor superfamily, is critical in the
understanding of the present study.

In mouse preclinical experiments, one group found that

overexpression of HER2 had no effect on the number of micrometastases in a brain-seeking
clone of a human breast cancer cell line, but it increased the number of large brain metastases
three-fold [70]. This suggests that HER2 promoted the colonization step of brain metastasis in
this breast cancer cell line, rather than driving the initial stages of the metastatic cascade [44],
and that therapies targeted at HER2 may inhibit the progression of already-present brain
metastases.
Animal model systems

HIGHLIGHTS
 Brain metastases originating from breast cancer tend to occur late,
after metastasis to the bone, lungs, and/or liver

that recapitulate many aspects

 Median survival from time of brain metastasis diagnosis for HER2+
and TNBC patients is on the order of months

of brain metastases are crucial

 Risk of brain metastasis is highest in stage IV breast cancer patients,
at 25-35% for HER2+ and 40-45% for TNBC

in our understanding of basic

 These high-risk patients are candidates for therapies focused on
prevention of brain metastasis formation

biology,

 HER2 may promote the final colonization step of brain metastasis

preclinical evaluation of novel

 Our group developed a mouse model of HER2+ and TNBC breast
cancer that can reliably recapitulate the latter steps of the metastatic
process in the brain

and

therapeutic

also

strategies.

for

the

As

mentioned above, one group
created a brain-seeking clone from the MDA-MB-231 breast cancer cell line. A different group
found that a variant of a TNBC cell line spontaneously metastasizes to the brain in 42% of mice
[69].

More recently, our group developed mouse models of breast cancer that reliably

metastasize to the brain [71]. In this model, tail-vein injection of both a HER2+ and a triplenegative breast cancer cell line led to a high rate (~67%) of brain metastases in SCID/Beige
mice; the cells, labeled with green fluorescent protein (GFP), could be easily identified after
brain resection by fluorescent stereomicroscopy.
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Furthermore, the utility of the model was

validated when genetic knockdown of a specific microRNA led to almost complete inhibition of
the formation of brain metastases.

This robust model could provide an effective platform to

advance not only the field of brain metastasis research but also treatments directed at breast
cancer brain metastases.

Cell Line

Vector

Subtype

Lung Mets

Brain Mets

SUM149

Empty

Triple-negative IBC

7/9

6/9

MDA-IBC3

Empty

HER2+ IBC

3/15

10/15

MDA-231

miR-141 OE

Triple-negative

10/10

5/9

SUM159

miR-141 OE

Triple-negative

7/12

1/10

Figure 2: Mouse Model of Inflammatory Breast Cancer. Our group has developed a mouse model of
metastatic breast cancer, where injection of 500k green fluorescent protein-labeled breast cancer cells
results in approximately 67% incidence in untreated SCID/Beige mice in the SUM149 and MDA-IBC3
cell lines. In cell lines with low baseline miR-141 and high E-cadherin, overexpression of miR-141 can
lead to the same incidence (MDA-231). In this thesis, the MDA-IBC3 line was used.

While there is an opportunity to vastly improve the outcomes of breast cancer patients
who develop brain metastases, current treatments have demonstrated a measurable, albeit small,
benefit.
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D. Brain Metastasis Treatment Options
For patients with brain metastases, many factors dictate the direction of therapy: performance
status, expected prognosis, number, location, and size of brain metastases, presence of
symptoms, suitability for surgical resection, and availability of options to control extracranial
disease.

Several groups have formulated guidelines for managing these patients, including the

National Comprehensive Cancer Network (NCCN) and the American Society for Radiation
Oncology.

Treatment options include surgical resection, whole-brain radiation therapy

(WBRT), and stereotactic radiosurgery (SRS).

WBRT consists of a series of low-dose

treatments to the entire brain, while SRS is used as an alternative to surgical resection to
irradiate a single brain metastasis.

No systemic therapies have been approved to specifically

treat brain metastases from solitary tumors in the United States, although data is available from
clinical trials [72].
Patients with a single metastatic brain lesion are assessed for their suitability for surgical
resection and SRS. Two studies demonstrated an advantage to using surgical resection followed
by WBRT compared to WBRT alone, with an increase in overall survival from 15 to 40 weeks
[40, 73]. The addition of SRS to WBRT versus WBRT alone has produced mixed results [74,
75].

However, these patients are rare, as it has been well-documented that solitary brain

metastases are uncommon [64-66].
Patients who present with limited brain metastases generally receive SRS, combined
SRS and WBRT, or WBRT [76]. Two studies found no differences in overall survival with the
addition to WBRT to SRS, compared to SRS alone [77, 78].

Surgery has a limited role in

patients with more than one brain metastasis. Both surgical resection and SRS are ineffective in
patients with multiple brain metastatic lesions, where WBRT is the principal treatment [76]. In
patients with poor performance status, best supportive care is also an option [72].
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There is little data to support specific treatment strategies in patients with recurrent or
progressive brain metastases.

The NCCN guidelines recommend that patients with stable

systemic disease should be considered for surgery, re-irradiation, or chemotherapy; patients with
systemic disease progression should be considered for best supportive care or re-irradiation.
Chemotherapy use in

HIGHLIGHTS
 In most cases, surgery is limited to treating patients with only one
detectable brain metastasis

the

 Stereotactic radiosurgery, which irradiates single metastatic sites, is
used in patients with limited brain metastases

metastases has been limited,

 Whole-brain radiation therapy is the principal treatment in patients
with extensive brain metastases

as

 Systemic agents are largely ineffective in treating brain lesions, as
many do not penetrate the blood-brain barrier

undergone several rounds of

 As the success of systemic agents in treating extracranial disease
improves patient survival, an increasing number of cancer patients
are presenting with and succumbing to brain metastases

chemotherapy prior to the

treatment

many

of

patients

of

brain

have

 Trastuzumab treatment was found to increase the relative risk of
developing brain metastases by over 50% in a meta-analysis

development

brain

 Brain treatment-related toxicity is difficult to evaluate

metastases and also because
of the exclusion of patients

with brain metastases from clinical trials [41]; the data that does exist is discouraging. One of
the major impediments to systemic agents effectively treating brain metastases is the bloodbrain barrier (BBB).
The BBB is formed by endothelial cells lining the cerebral vasculature, and separates
the cerebrospinal fluid (CSF) from the systemic circulation.

Tight junctions between the

endothelial cells create a physical barrier, forcing molecules to pass through cells rather than
around them.

The endothelial cells express large amounts of active transporters, which pump

certain substances out of the cells and back into the systemic circulation, away from the brain
parenchyma. The molecules that are able to pass from the blood into the brain tend to be small
and lipophilic, unrecognized by the efflux pumps [79]; however, most standard chemotherapy
agents are substrates of these pumps and do not cross into the CSF [80, 81]. When lesions in the
brain grow beyond a 1-2 mm diameter, the BBB becomes structurally compromised [82],
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increasing BBB permeability and permitting chemotherapeutic agents to enter the CSF.
Unfortunately, the lack of success in treating brain metastases indicates that if the BBB is
compromised near a lesion, there is insufficient accumulation of chemotherapy agents in the
brain to effect a response.
Trastuzumab, the monoclonal antibody that is used as a systemic agent in patients with
HER2+ breast cancers, does not cross the BBB.

A meta-analysis of clinical trials using

trastuzumab to treat breast cancer patients revealed a relative risk of brain metastasis of 1.57
[83].

This could be due to improvements in systemic control with trastuzumab, prolonging

patient survival and increasing the timeframe through which brain metastases can become
symptomatic.

In addition, it has been proposed that trastuzumab alters the underlying biology

of invasive breast cancer cells in such a way as to preferentially drive them towards the brain.
Lapatinib, an inhibitor of both EGFR and HER2, is indicated for use with the antimetabolite capecitabine for the treatment of patients with advanced or metastatic HER2+ breast
cancers who have received a prior systemic therapy [72]. Lapatinib can reach therapeutic levels
in brain metastases, although it does not cross the intact BBB [84].

A trial comparing the

combination of lapatinib and capecitabine versus WBRT alone is in the planning stages; several
trials of other HER2-targeting inhibitors for the treatment of breast cancer brain metastases are
in progress [72].
Evaluating toxicity from therapies directed at brain metastases is difficult, as morbidity
due to the treatment must be differentiated from the morbidity due to the brain lesion(s).
Nevertheless, it is critical to understand the potential neurocognitive decline that patients could
exhibit after the course of treatment, especially if the intracranial metastases respond to therapy,
prolonging patient survival.

Neurological toxicity associated with whole-brain radiation therapy

will be discussed in detail in the following section.
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Major improvements in local and systemic therapies are increasing patient survival times
and, as a result, more patients are presenting and then succumbing to brain metastases. Despite
the use of surgical resection, radiation therapy, and systemic therapies in breast cancer patients
with brain metastases, outcomes remain extremely poor.
metastases

include

enhancing

therapeutic

delivery

to

Novel strategies to treat brain
the

radiosensitizers, or the implementation of preventative agents.

brain,

the

development of

The use of whole-brain

irradiation (WBI) as a preventative strategy, known as prophylactic cranial irradiation, has
improved overall survival in non-small cell lung cancer and acute lymphoblastic leukemia
patients who are at high risk of developing brain metastases – whether or not the same strategy
could be used effectively for high-risk breast cancer patients remains unresolved.

Figure 3: Treatment guidelines for patients with brain metastases . Common treatments for patients
with brain metastasis include surgery, SRS, WBRT, and chemotherapy.
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SECTION III. PROPHYLACTIC CRANIAL IRRADIATION
The risk of brain metastasis is high when considering the advanced stages of certain primary
cancers, such as small-cell lung cancer, acute lymphoblastic leukemia, and breast cancer. Even
with major advances in multimodal therapy, the patients who are diagnosed with brain
metastasis have very short survival times, usually less than one year from the time of diagnosis.
As mentioned in the preceding section, novel strategies to treat brain metastases are being
explored, but improvements in the treatment of brain metastases continue to be marginal.
The presence of non-symptomatic, undiagnosed micrometastases in the brain of many
advanced stage cancer patients was also noted above. This pool of lesions below the threshold
for clinical detection presents both a problem – the dormant cells could become activated at any
point, even years after the primary tumor has been cured, leading to overt brain metastases that
have major adverse consequences for the patient – and an opportunity – it may be possible to
use therapeutics to treat the micrometastases or to alter the brain microenvironment in such a
way as to reduce or altogether inhibit the future develop of brain metastases.

In addition,

prophylactics may minimize neurocognitive impact in patients, whereas typical therapies for
brain metastases are each associated with side effects that adversely impact quality of life.
To be successful, prevention strategies in general require several factors, including a
high incidence rate of the event to be prevented, efficacy and durability, and acceptable levels of
morbidity [85].

The most promising preventative approach in patients with advanced disease,

known as prophylactic cranial irradiation (PCI), utilizes whole-brain irradiation (WBI) in
patients who are at high risk of developing brain metastases.

This technique has been used

successfully to improve intracranial control and survival for patients with small-cell lung cancer
and children with acute lymphoblastic leukemia, and there is rising interest to explore the
potential for PCI in high-risk breast cancer patients.
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A. Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia (ALL) refers to a group of lymphoid disorders characterized by
the overproduction of cancerous, immature white blood cells, known as lymphoblasts, in the
blood, bone marrow, and other organs. ALL is most common in children around the ages of 4-5
years, with a peak incidence of five per 100,000 [86].

Prior to the adoption of prophylactic

techniques in children with ALL, the brain accounted for roughly 75% of recurrences [87]; with
modern treatments, only 5-10% of children with ALL relapse in the brain [88].
Due to the high rate of relapse in the brain, PCI was introduced over four decades ago as
a prevention strategy in children with ALL who were at high risk for brain relapse. In the initial
studies using PCI (24 Gy), relapse was observed in the brain in 4% of children who underwent
PCI compared to 67% of children in the non-irradiated control group [89]. PCI is currently used
in less than 20% of children with ALL, and overall five-year survival rates for all child ALL
patients are above 85% [90].
When PCI is used in children with ALL, it is most often combined with either systemic
or intrathecal (direct delivery to brain, rather than through systemic circulation) chemotherapy.
Due to the intrinsic radiosensitivity of leukemic cells and improvements in chemotherapy
regimens, the PCI doses administered to children were lowered to 12-18 Gy, in ten fractions.
Because these patients are children and the long-term survival rates are high, treatmentrelated late effects are a major concern.

The use of PCI in childhood ALL has been steadily

reduced since the late 1970s, as it can cause neurocognitive impairment and increased incidence
of second cancers twenty years after the initial diagnosis of ALL [91]. Furthermore, two recent
studies have shown that by intensifying systemic and intrathecal chemotherapy, PCI can be
omitted without compromising overall survival [92, 93].
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B. Small Cell Lung Cancer
Small cell lung cancer (SCLC) accounts for roughly 15% of all lung cancers, and is
characterized by its rapid doubling time and early development of widespread metastases.
Although SCLC responds initially to radiation and chemotherapy, most patients die from
recurrent disease, with five-year survival rates ranging from 30% for patients with local disease
to 2% for patients with advanced disease [94].
Brain metastasis is common in patients with SCLC: 15% of patients present with brain
metastases at the time of diagnosis, and approximately half of patients in complete remission
after treatment for limited disease SCLC will relapse in the brain, causing serious impairment of
patient survival and quality of life [95].

For patients treated for SCLC, median survival after

brain relapse is six months [96].
PCI was introduced in the early 1980s to reduce the incidence of brain metastasis in
patients with both limited and extensive disease SCLC [96]. A meta-analysis, based on SCLC
patients (85% limited disease, 15% extensive disease) in complete remission that were included
in seven randomized phase III studies, reported a decrease from 59% to 33% in the cumulative
incidence of brain metastasis three years after PCI; this corresponded to an overall survival
increase from 15.3% to 20.4% in patients who received PCI [49].

In the same analysis, the

authors noted a significant trend towards decreased incidence of brain metastasis with both
higher radiation dose and earlier administration of PCI after the start of SCLC treatment. For
patients with limited disease SCLC who respond to first-line treatments, 25 Gy in ten fractions
is recommended for PCI [96].
Similarly, PCI is also standard treatment for all patients with extensive disease SCLC.
In a randomized phase III trial comparing PCI (20-30 Gy) versus observation, PCI significantly
reduced the cumulative incidence of brain metastasis at one year from 40.4% to 14.6%, with an
associated increase in one-year overall survival from 13.3% to 27.1% [97].
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Although

HIGHLIGHTS

toxicity

 Patients with certain primary cancers, in advanced stage, are at high
risk of developing brain metastases

from PCI is much less of a

 Even with advances in multimodality therapy, the prognosis of
patients with brain metastases is very poor

concern

 In experimental studies and in autopsy reports from deceased cancer
patients, micrometastases below the threshold for clinical detection
have been identified, suggesting a dormant tumor cell population
that had yet to be activated and cause a detectable metastasis

 Prevention strategies require a high incidence rate of the event to be
prevented (high risk of brain metastasis), efficacy and durability of
the treatment (prevention of metastasis to extend patient survival),
and acceptable levels of morbidity (minimal cognitive impairment)
 Prophylactic cranial irradiation uses whole-brain radiation therapy
as a preventative measure in patients at high risk of developing
brain metastases
 This technique has been used for decades in children with acute
lymphoblastic leukemia and adults with small cell lung can cer to
reduce the incidence of brain metastases and to significantly
improve overall survival in these high-risk patients

in

patients

with

SCLC compared to children
with ALL, there are efforts to
identify patients at high risk
of

developing

brain

metastases. For example, one
group reported that response
to chemotherapy and weight
loss of less than 5 kg at

presentation were independent predictors of future brain metastasis [98].

C. Non-Small Cell Lung Cancer
Non-small cell lung cancer (NSCLC) accounts for the other 85% of lung cancers, and is the
leading cause of cancer-related deaths for both men and women in the United States with fiveyear survival rates ranging from 1-50% [99].

The incidence of brain metastasis in NSCLC

patients ranges from 13-54% and half of these patients will die from brain metastasis
progression [96].

The addition of chemotherapy to the treatment of patients with locally

advanced NSCLC has substantially improved the prognosis of patients in the past fifteen years;
however, the longer resulting survival times combined with the ineffectiveness of chemotherapy
agents in the brain have actually led to increased risk among NSCLC patients of developing
brain metastases [100].
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All patients after CR
to chemotherapy

Poor response to chemo
Overt CNS disease
12-18 Gy (1.8-Gy fxs)

Indications

Dose

20 Gy/5 fxs to 30 Gy/10 fxs

Following
chemotherapy

Significant Benefit to PCI

Observed: 59%
PCI: 15%

Extensive Disease

NSCLC
Stage III-IV

30 Gy/15 fxs

Undetermined

No Benefit from PCI

Observed: 22-55%
PCI: 4-13%

Adapted from these publications:
1) Bovi JA and White J. Current Oncol Rep 2012, 14:55-62.
2) Aur R, Hustu H, and Verzosa M. Blood 1973, 42(3): 349-357.
3) Pui C, et al . Blood 2012, 120(6): 1165-1174.
4) Pui C, et al . New England Journal of Medicine 2003, 349(7): 640-649.
5) Auperin A, et al . New England Journal of Medicine 1999, 341(7): 476-484.
6) Slotman B et al . New England Journal of Medicine 2007, 357(7): 664-672.
7) Paumier A, Cuenca X, and Le Pechoux C. Cancer Treatment Reviews 2011, 37(4): 261-265.
8) Gore EM, Bae K, and Wong S. J Clin Oncol 2009, 27(15 S).
Table 2: Clinical Data for Prophylactic Cranial Irradiation in SCLC and ALL Patients. PCI reduces the incidence of brain metastasis in
patients with ALL, SCLC, and NSCLC, althought improvements in overall survival have only been observed in ALL and SCLC patients.

ALL: Acute lymphoblastic leukemia; SCLC: Small cell lung cancer; NSCLC: Non-small cell lung cancer
PCI: Prohylactic cranial irradiation; CR: complete response; Gy: Gray; fx: fraction

8 Gy/1 fx to 40 Gy/20 fxs

Significant Benefit to PCI

Significant Benefit to PCI

Overall Survival

Observed: 40%
PCI: 33%

Observed: 67%
PCI: 4%

Limited Disease

SCLC

Incidence of Brain
Metastasis

ALL
Children

Several groups have addressed this trend by investigating the use of PCI in patients with
locally advanced NSCLC. In five of six randomized studies, the NSCLC patients who received
PCI had significantly lower incidence of brain metastasis than patients in the control arm
(usually by more than 50%); the sixth study found a trend in the same direction. However, no
benefit in overall survival was detected in any of these reports, likely due to low sample sizes
and high systemic failure rates [101-106]. Currently, PCI is not considered standard of care for
patients with locally advanced NSCLC; nevertheless, due to the improved intracranial disease
control despite the lack of improvement in overall survival, the role of PCI in NSCLC continues
to be investigated.

D. Breast Cancer
Brain metastases lead to compromised survival and a poor quality of life in breast cancer
patients and, therefore, the use of prophylactic cranial irradiation in breast cancer patients at
high risk of developing brain metastases has garnered increased interest in recent years.
Moreover, with an aging population and improvements in extracranial disease control with
trastuzumab and other systemic agents, the number of breast cancer patients who are diagnosed
and succumb to brain metastases will continue to rise.
As mentioned in the preceding section, there is considerable evidence that patients with
advanced stage, HER2+ or triple-negative breast cancers have a propensity for developing brain
metastases.

This differs vastly from the entire breast cancer patient population, which has an

estimated 5% risk of developing brain metastasis during the course of their disease. Further, the
incidence of brain metastasis is too low in early-stage breast cancer for prevention to be a
reasonable option, as the patients would be subject to unnecessary toxicity.

Conversely, the

high-risk cohort which already has extracranial metastases has an incidence of brain metastasis
that is high enough (25-45%) to consider PCI.
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Figure 4: Stratification of Breast Cancer Patients at Risk of Brain Metastasis. Specific breast cancer
patient cohorts are at increased risk of developing brain metastases, broken down by disease stage,
molecular subtype, and other factors. The patients at the highest risk of developing brain metastases are
within the stage IV, HER2+ or TNBC subtype cohorts.

Other variables besides molecular subtype are reported to have an association with risk
of brain metastasis in breast cancer patients, including age and histologic grade; however, taken
individually these factors are qualitative. To quantify the risk of brain metastasis for individual
breast cancer patients, rather than the risk of an entire patient cohort, Ibrahim and colleagues
constructed a nomogram by combining clinical and pathologic variables using a multivariate
model [107].

In the patient set used to develop the nomogram, the area under the receiver

operating characteristic curve (AUC) was 0.68, while the AUC was 0.74 in the validation set.
The factors independently associated with higher probability of brain metastasis were younger
age, higher histologic grade, triple-negative and HER2+ status, shorter delay between breast
cancer diagnosis and first metastasis, and more than one non-brain metastatic site. Based on the
nomogram, the range of probabilities for an individual non-brain metastatic breast cancer patient
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to develop brain metastasis is approximately 5-50%.

The same group is constructing a similar

nomogram for inflammatory breast cancer patients.
The clinical utility of

HIGHLIGHTS
 There is a breast cancer patient cohort – Stage IV, TNBC or HER2+
-- that has a high enough risk of developing brain metastasis to
consider prevention strategies such as PCI
 Recent efforts have attempted to quantify the risk that individual
patients have of developing brain metastasis, which would enable
selection of individual patients for clinical trials with PCI

 In one study, ten breast cancer patients in complete remission
received PCI: two patients had central nervous system failures and
three survived long enough to exhibit severe cognitive decline
 In a separate study, WBRT reduced the cerebral deaths threefold in
a breast cancer population with occult (detected by MRI but
asymptomatic) brain metastases, although there was no
improvement in overall survival

this nomogram is to further
define

the

breast

cancer

patients with the highest risk
of

developing

brain

metastases, and who were
most likely to benefit from a

 The brain is a late-responding tissue to irradiation, and is one of the
least radiosensitive organs

preventative strategy such as

 Common toxicities observed in WBRT patients and in SCLC PCI
patients are quality of life factors (hair loss & fatigue) and
neurocognitive decline (memory loss)

PCI.

For

example,

selecting

only

the

if

patients

with a greater than 25% probability of developing brain metastasis, only 30% of the population
(of non-brain metastatic breast cancer patients) would be treated, but roughly 80% of the
subsequent brain metastases would potentially be prevented [107].

An optimal percentage of

high-risk breast cancer patients could be selected for clinical trials evaluating the efficacy of
PCI.
No large-scale studies evaluating the use of PCI in breast cancer patients have been
conducted; however, we can draw insight from smaller studies.

In one investigation, stage

IIIB/IV breast cancer patients who responded to anthracycline-based induction chemotherapy
underwent autologous marrow transplantation, after which the ten patients in continued
remission were referred for PCI [108]. In those ten patients treated with PCI, there were two
central nervous system failures (20% incidence post-PCI), but no comparisons could be drawn
with the non-PCI group because of inherent bias in the study design.
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In a separate study, Niwinska et al. [109] compared the efficacy of WBRT to treat
HER2+ breast cancer patients with symptomatic (overt) versus non-symptomatic (occult) brain
metastases. There was a threefold decrease in the number of cerebral deaths when patients with
occult brain metastases were treated with WBRT as compared to the symptomatic patients;
however, overall survival was not affected.

They concluded that an early onset of WBRT can

reduce the occurrence of severe neurologic complications and can have a major impact on
quality of life.

Nonetheless, the study had significant limitations, including a relatively small

sample size and a large rate of extracranial failure.

With improvements in the treatment of

extracranial disease with systemic agents, a threefold decrease in cerebral deaths would likely
translate to improvements in overall survival.

Further, this study looked at HER2+ breast

cancer patients with occult brain metastases that were treated with WBRT; prophylactic cranial
irradiation would be administered to high-risk patients before the onset of (a)symptomatic brain
metastases or to prevent intracranial relapse.
Finally, a recent study out of the UK looked at the effect of PCI in HER2+ breast cancer
patients with locally advanced or metastatic disease as the first relapse [Canney].

The

recruitment target was 390 patients to randomize into the PCI or non-PCI arm; unfortunately,
only 51 patients were enrolled, mostly due to the reluctance of physicians to approach patients
recently diagnosed with metastatic disease about the possibility of PCI.

While the incidence

was decreased in the PCI group – 30 Gy in ten fractions – from 32% to 21%, this was not
significant. It is important to note that there was no additional toxicity associated with the PCI.
The prevention of brain metastases with PCI could substantially improve the survival
and quality of advanced stage breast cancer patients.

Additional investigations are needed to

precisely define the breast cancer patients that would most benefit from PCI, ideal timing of
delivery, dose and fractionation schedule, and systemic agents to be administered concurrently
to PCI.
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E. Neuropsychological Problems
The importance of identifying the breast cancer patients most likely to develop brain metastases
stems in large part from the potential toxicity associated with WBRT.

Any intervention must

weigh the benefits against the potential morbidity, and only patients with high enough risk of
developing brain metastases would be considered for PCI in the event that the technique is
adopted clinically.
It is generally accepted that DNA damage occurs in the minutes to hours following
irradiation; cell death in the days following irradiation; early effects (toxicity) are caused by the
death of a large number of cells in rapidly proliferating tissues, occur within days to weeks after
irradiation, and is generally repaired rapidly because of the proliferation rate; and late effects
(toxicity) manifest in slowly proliferating tissues, in the months to years following irradiation,
and is never completely repaired. The principal cells in the brain are either non-proliferating or
slowly proliferating, and consequently it is a late-responding tissue.
considered one of the least radiosensitive organs [110].

Furthermore, the brain is

Nevertheless, there are common

adverse effects observed in patients treated with PCI or WBRT that need to be mentioned.
In the case of PCI in SCLC, patients are likely to present some neurocognitive
abnormalities at baseline, but the whole-brain irradiation can lead to further decline in many of
the treated patients [111].

First, quality of life is adversely affected by PCI, but the impact

seems to be limited to fatigue and hair loss. A different study found that 75% of PCI patients
had neurologic complaints such as difficulty with walking or balance and memory loss.
Another sixty-five percent had abnormal neuropsychologic testing, generally due to memory or
IQ impairment; however, no baseline information was collected so the effect of PCI is not
definitive [112].

The same study also found that higher radiation fraction sizes or concurrent

chemotherapy was associated with greater abnormalities.

A separate study identified increasing

age as a risk for neurocognitive decline [113], which indicates that not only do we have to
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consider patient selection for PCI from the vantage point of benefit but also from risk (toxicity).
In conclusion, it seems that the major adverse events from PCI are likely to be a decrease in the
quality of life (fatigue and hair loss) and neurocognitive decline (most notably, memory).
In the small breast cancer PCI study mentioned in the previous section, Huang and
colleagues found that of the ten breast cancer patients who received PCI, three lived long
enough to exhibit signs of neurocognitive decline [108].

The prescription was 36 Gy in 20

fractions – higher than is typical for SCLC patients – and the neurocognitive decline was noted
at 9 months, 4 years, and 5 years post-PCI in the three patients. Unfortunately, no control
groups were included in the study, and due to the small sample size no strong conclusions could
be drawn.

SECTION IV. SCOPE OF DISSERTATION
Breast cancer patients whose tumors metastasize to the brain have extremely poor prognosis,
and treatment options are severely limited due to the poor penetration of the blood-brain barrier
by systemic agents. From both animal studies and autopsy reports, it is evident that there is a
large population of micrometastases – below the threshold for clinical detection but with the
potential to form overt, life-threatening metastases – in many advanced stage cancer patients. In
acute lymphoblastic leukemia and small cell lung cancer patients at high risk of developing
brain metastases, this population of micrometastases has been effectively targeted, with
prophylactic cranial irradiation, in an attempt to slow the incidence of overt brain metastases
and improve patient survival.

Patients with stage IV, HER2+ or triple-negative breast cancer

are at high risk of developing brain metastases; whether prophylactic cranial irradiation can
benefit these patients is a gap in knowledge that needs to be addressed. The central hypothesis
of this dissertation is:
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Prophylactic cranial irradiation will reduce the incidence of brain metastasis
by 50% in a mouse model of metastatic, HER2+ inflammatory breast cancer

Three specific aims will be addressed in the present work:
Specific Aim 1: Show that a dose of 4 Gy will reduce the incidence of brain metastasis only
when administered as a prophylactic
 Examine if irradiation prior to cell injection primes the brain for metastasis
 Determine if there is an association between the incidence of brain and lung metastasis
Specific Aim 2: Develop a computational model of radiation dose-response for subclinical
breast cancer based on the metastatic HER2+ mouse model
 Recapitulate the experimental non-irradiated mice data by optimizing input parameters
 Validate the model assumptions and inputs by performing a limiting dilution assay
Specific Aim 3: Demonstrate that 4 Gy prophylactic cranial irradiation in the computational
model reduces the incidence of brain metastasis by 50%
 Investigate if the experimental incidence can be realized by the assumptions used to
develop the model
 Demonstrate that delaying treatment introduces a dose threshold below which no
reduction in the incidence is observed

By examining the use of PCI in a mouse model of metastatic HER2+ inflammatory breast
cancer, we will move closer to understanding the utility of using PCI in breast cancer patients
who are at high risk of developing brain metastases.
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CHAPTER 2: PROPHYLACTIC CRANIAL IRRADIATION
REDUCES BREAST CANCER BRAIN METASTASIS IN MICE
SECTION I. INTRODUCTION
We elected to investigate the utility of whole-brain irradiation to prevent brain metastases – a
technique known as prophylactic cranial irradiation (PCI) – in a mouse model surrogate of
breast cancer patients at high risk of developing brain metastasis.

As mentioned in the

introduction, clinicians are now able to identify a subset of breast cancer patients who have a
risk of developing brain metastasis upwards of 30%. Because the outcomes of breast cancer
patients with brain metastasis are abysmal, even with the use of multimodality therapies,
prevention strategies are attractive.

PCI has been used in children with acute lymphoblastic

leukemia and adults with small cell lung cancer to both reduce the incidence of brain metastasis
and to improve overall survival, and there is interest in running clinical trials with high-risk
breast cancer patients in order to evaluate the efficacy of PCI.

My work, described in the

present chapter, addresses the question of whether micrometastatic breast cancer in the brain is
treatable with a PCI dose, and if any observed effect is durable.
This chapter represents the principal line of inquiry for my thesis, for which the
hypothesis is that prophylactic cranial irradiation will reduce the incidence of brain
metastasis by 50% in mouse model of metastatic, HER2+ inflammatory breast cancer.
The specific aim that will be addressed in this chapter is to show that a dose of 4 Gy will reduce
the incidence of brain metastasis only when administered as a prophylactic. There are two subaims: 1) examine if irradiation prior to cell injection primes the brain for metastasis, and 2)
determine if there is an association between the incidence of brain and lung metastasis.
In SCLC patients who are diagnosed with brain metastases and treated with WBRT, the
total dose is usually 30 Gy; in the case of SCLC PCI, the total dose is 25 Gy (i.e. the WBRT and

32

PCI doses are very similar). Therefore, the aim for this experiment was to identify if there is a
dose that would be effective for PCI but not for WBRT.
In order to investigate my hypothesis, I utilized the mouse model that was recently
developed in our lab [71].

In this model, two-thirds of untreated mice developed brain

metastases, in two separate inflammatory breast cancer cell lines, when SCID/Beige mice were
tail-vein injected with five hundred thousand cells.

Eight weeks after injection, the mice were

sacrificed and we were able to observe the green fluorescent protein-labeled metastases under a
stereomicroscope. In the past, metastasis has been a difficult process to study due to the death
of experimental systems; this model allows us to examine therapies which may be effective in
mitigating the adverse effects caused by brain metastases, and forms the backbone of this
chapter.
A second major limitation which would have hindered this study in the recent past is the
lack of precision of small-animal radiation research.

Fortunately, several platforms have been

developed in the past decade that permits the delivery of x-rays to a specified area with
excellent precision and accuracy.

One such platform is the X-RAD C225x, developed by

medical physicists at the University of Toronto [114].

Here, I exploit this increased

translational potential of small animal radiation research in order to investigate how PCI affects
the incidence of brain metastasis in mice.
For the experiment in this chapter, I sacrifice half of the mice at four weeks after tailvein injection of breast cancer cells, and the other half at eight weeks post-injection.

The

rationale for having two endpoints is to understand the time dynamics of any differences
observed between the treatment groups.

Specifically, if PCI decreases the incidence of brain

metastasis four weeks after cell injection, would the effect persist at the eight-week endpoint? If
so, then it is likely that PCI has a durable effect in decreasing the incidence of brain metastasis;

33

if not, then it would seem that PCI merely delays the incidence of brain metastasis, rather than
preventing it outright.
In this study, there are four different time points at which the mice are treated with WBI
(and one untreated control), and all groups are treated in the exact same manner. The major
focus of this thesis is PCI, which is the group of mice irradiated five days after tail-vein
injection of breast cancer cells. The three other irradiated groups serve as controls:
1. One group of mice receives WBI two days before cell injection; the question this
addresses is if a mechanism other than radiation-induced cell death or senescence is
responsible for any observed decrease in the incidence of brain metastasis. Only if the
PCI displays decreased incidence of brain metastasis compared to both the control and
this group could I conclude that the mechanism is primarily due to cell death of induced
senescence.

Previous work has demonstrated that irradiation of the mammary gland

causes unirradiated, non-transformed cells to form tumors in the mammary gland at a
significantly higher rate than would be observed in the unirradiated mammary gland
[115].
2. One group of mice receives WBI three weeks after cell injection; many single cells
should have grown into small masses by this point, so I am effectively comparing a
therapeutic against a prophylactic, as the only difference between the groups is the day
of irradiation.

Inclusion of this time point would specify that any observed effect that

PCI has on the incidence of brain metastasis is due to the timing of the irradiation (i.e.
prophylactic), rather than due to a dose high enough to eradicate overt or occult
metastases.
3. One group of mice receives WBI six weeks after cell injection; the rationale is the same
as for the mice treated with WBI three weeks after cell injection.
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The last aspects of the experiment I will rationalize are the conditions for the WBI. If PCI
was used clinically in breast cancer patients, it would be administered in several fractions at a
total dose of approximately 25 Gy. Here, I am irradiating each mouse with a single fraction of 4
Gy.

The reasoning behind the single fraction, as opposed to two or more fractions, is to

simplify the experiment: Because over sixty mice are being irradiated, each additional fraction
adds significant time and cost and, perhaps more importantly, introduces the problem of
between-fraction time variability.

Further, the scientific benefit of utilizing multiple fractions,

rather than one, in this experimental system is dubious.

I use a dose of 4 Gy as this is

comparable to other treatment doses used for the mouse brain. Last, I am irradiating the brains
with two lateral opposed fields, at 2 Gy each. The purpose of this is to administer the dose to
the entire brain as uniformly as possible, and is the same setup used clinically.

Based on information in the literature as well as from previous work done in our lab with
the mouse model of breast cancer brain metastasis, I expected to see the following results:
1. Reduced incidence of brain metastasis in mice that were treated with PCI compared to
control; similarly, reduced brain metastasis tumor burden in PCI-treated mice (number
and area of brain metastases)
2. No differences in the incidence of lung metastases between the different groups
3. Approximately 67% of non-treated mice develop brain metastases [71]
4. Approximately 20% of mice develop lung metastases [71]
5. Because breast cancer brain metastasis can be a secondary metastasis that arrives in the
brain via the lungs, mice with lung metastases will have a greater incidence of brain
metastasis than mice without lung metastases
6. Mice with brain metastases will display symptoms of disease through weight loss
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SECTION II. METHODOLOGY
A. Cell culture
MDA-IBC3, a HER2+ inflammatory breast cancer cell line, was generated in our lab and has
been described previously [116]. MDA-IBC3 was cultured in Ham’s F-12 media supplemented
with 10% fetal bovine serum (FBS), 1 µg/mL hydrocortisone, 5 µg/mL insulin, and 1%
antibiotic-antimycotic.
37°C.

This cell line was maintained in humidified conditions with 5% CO 2 at

MDA-IBC3 cells were passaged approximately every four days prior to injecting the

cells into mice.
MDA-IBC3 was previously transfected [71] with a plasmid that encodes for green
fluorescent protein (GFP).

Briefly, the plasmid was purchased from Systems Biosciences and

was packaged with pRSV-Rev, pMDLg-pRRE, and pCMV-VSVG in 293T cells. MDA-IBC3
was then transduced via lentivirus as we described previously [116].

B. Mouse Strain
Three- to five-week-old female immunocompromised SCID/Beige mice (Harlan, USA) were
housed and used in accordance with the institutional guidelines of the University of Texas M.D.
Anderson Cancer Center under the Institutional Animal Care and Use Committee approved
protocol (ACUF 07-08-07213). M.D. Anderson Cancer Center’s animal care and use program
has been fully accredited by the Association for the Assessment and Accreditation of Laboratory
Animal Care International (AAALAC).

Mice were monitored regularly and were weighed

weekly.
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C. Intravenous Tail-Vein Injection
MDA-IBC3 cells were prepared for injection by trypsinizing all cells and then neutralizing with
culture media. The cells were washed twice with PBS before counting and placed in sterile 1.5mL Eppendorf tubes at a concentration of 2.5 x 10 6 cells/mL PBS. Cells were kept on ice until
ready for injection.
Five hundred thousand MDA-IBC3 cells in 200 µL PBS were injected via tail vein with
27-gauge needles into each 6- to 8-week-old mouse.

D. Irradiation
Mice received WBI at different time points with respect to tail-vein injection of cells (see Figure
5).

Twenty-three mice were used as non-irradiated controls; twenty were irradiated two days

prior to cells injection; twenty were irradiated five days after injection, the prophylactic cranial
irradiation group; seventeen were irradiated three weeks after irradiation, and eight were
irradiated six weeks after injection.
To perform the WBI, mice were placed in an inhalation anesthesia induction chamber
(isoflurane: 5% induction, <3% maintenance).

Once anesthetized, each mouse was transferred

to the imaging and treatment stage in the X-RAD 225 Cx small-animal irradiator (PRECISION
X-RAY, North Branford, CT, USA), which includes a nose cone through which anesthesia was
maintained with isoflurane.

Once on the imaging and treatment stage, a scout cone-beam

computed tomography image – with a 2.0-mm aluminum filter – was run for each mouse at 40
kVp and 2.50 mA in order to manually set the isocenter.
The same treatment plan, developed with the PilotXRAD 1.10.4 software, was used for
all mice that were irradiated. Each mouse received a single fraction of 4 Gy for the whole-brain
irradiation, with two 2-Gy lateral opposing fields. The treatment field (Figure 6) was defined by
a 15-mm diameter (at isocenter) copper collimator, and a 0.3-mm copper filter was used. The
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treatment was performed at 225 kVp and 13.0 mA, at a rate of approximately 320 cGy per
minute (36-38 seconds for each field).

E. Fluorescent Microscopy
Mice were euthanized at either four or eight weeks after injection (Figure 5), and the lungs and
brain were collected in 10% formalin. All organs were evaluated for metastatic colonization by
assessing GFP levels with the Nikon AZ100 fluorescent stereomicroscope at 20X magnification
(Tokyo, Japan).
each organ.

The primary endpoint was the presence or absence of metastasis (binary) in

This was evaluated visually with the Nikon NIS-Elements software.

Also, the

number of metastases per mouse was counted for mice sacrificed at the eight-week endpoint.
Metastatic brain tumor burden for mice at the eight-week endpoint was measured using
the Nikon NIS-Elements software. Briefly, the area of each metastatic focus was determined by
using the object count automation within the software. The areas from each of the foci, visible
from either the top or bottom two-dimensional images of the brain, were added to give the total
tumor burden, in terms of square millimeters.
Images were prepared by setting a lower threshold for GFP intensity in order to subtract
the autofluorescence background and then by overlaying the result on a differential interference
contrast (DIC) image.

F. Statistical Analysis
The Fisher’s exact test was used to compare the incidence of metastatic colonization to the brain
and lung in the different treatment groups. The non-parametric Kruskal-Wallis test was used to
evaluate the overall effect of different treatments on the number and size of brain metastases,
and Dunn’s test was used to compare the number and size of brain metastases between each
group. P-values of less than 0.05 were considered statistically significant.
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Figure 5: Design of Prophylactic Cranial Irradiation Experiment. SCID/Beige mice were injected
with five hundred thousand GFP-labelled MDA-IBC3 cells, via tail vein. Four of the five groups
received 4 Gy whole-brain irradiation at different time points. The mice were sacrificed at four and eight
weeks after cell injection, at which point the brains and lungs were excised to evaluate metastases.
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Figure 6: Setup for Irradiation of Mice. Irradiation of mouse brains was carried out in the X-RAD
225Cx, a dedicated small-animal irradiator. In the machine, mice are anesthetized with isoflurane
through the nose cone. A scout cone-beam CT image is used to set the isocenter (bottom panel), and a
15-mm collimator (top right) confines the treatment field to the brain. The circle in the bottom panel
represents the 15-mm diameter treatment field. All treated mice were irradiated with 4 Gy whole-brain
radiation, administered in one fraction with two 2-Gy, opposing lateral fields.
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SECTION III. RESULTS
A. Four-Week Endpoint
Thirty-one to -two days after tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into
SCID/Beige mice, 43 mice were sacrificed. Of these 43 mice, 13 were non-irradiated controls,
10 were irradiated two days prior to cell injection (pre-irradiation group), 10 were irradiated five
days after cell injection (prophylactic cranial irradiation [PCI] group), and 10 were irradiated
three weeks after injection (3-week treatment group).
After sacrifice, the excised brain and lung tissue from each mouse was evaluated for the
presence of GFP-labelled metastases using fluorescence stereomicroscopy.
classified

as

All organs were

positive or negative through visual inspection on the stereomicroscope.

Representative images of GFP-labelled metastases in brain and lungs four weeks after injection
are depicted in Figure 7.
The results for the number of mice in each group with brain metastases are shown in
Table 3.

Ten mice in the control group developed brain metastases (77%), consistent with the

results previously reported by our group [71].

Interestingly, all ten mice in the pre-irradiated

group developed brain metastases (not significant compared to control).

In the prophylactic

cranial irradiation group, only two mice developed brain metastases after four weeks (20%),
consistent with my hypothesis that PCI would reduce the incidence of brain metastasis. This
was significantly lower than the incidence of brain metastasis in two of the other groups, and
suggested a trend in the third (vs. control, p = 0.01; vs. pre-irradiation group, p = 0.0007; vs. 3week treatment group, p = 0.07). The treatment of mice with 4 Gy WBRT at three weeks after
cell injection had no impact on the number of mice that developed brain metastases compared to
the control.
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The number of brain metastases per mouse was compared between the five different
groups (Figure 8).

Overall, the number of brain metastases per mouse (p = 0.004) was

significantly affected by the treatments at different time points.

Further, prophylactic cranial

irradiation significantly decreased the number of metastases per mouse compared to two of the
three other groups ([number of brain metastases per mouse, PCI: vs. control, p < 0.03; vs. preirradiation group, p < 0.003; vs. 3-week treatment group, p = 0.25).
Excised lungs from the sacrificed mice were also examined for the presence of
metastases. Because the 4 Gy was administered at various time points only to the brain, we did
not expect to see any differences in the incidence of lung metastasis between the four groups.
As Table 4 shows, there were no significant differences.
The different groups were also compared based on the number of mice in each group
that had either lung or brain metastases.

As shown in Table 5, there were no significant

differences.
We expected to see that mice with lung metastases would have a higher incidence of
brain metastasis compared to mice that did not have lung metastases. This was the case for the
mice sacrificed at four weeks post-injection (76% vs. 40%, p = 0.06), indicating a trend (Table
6).
Finally, the weight of the mice increased steadily up until the point at which they were
sacrificed, indicating that the brain metastases which were present had not yet caused serious
morbidity (Figure 9).
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Presence of Brain Metastases: 4-Week Endpoint
0 Gy

10/13

77%

4 Gy WBI @ 2d Pre-injection

10/10

100%

4 Gy WBI @ 5d Post-injection

2/10

20%

4 Gy WBI @ 3wk Post-injection

7/10

70%

p < 0.05
p < 0.001

p < 0.10

Table 3: Presence of Brain Metastases at Four-Week Endpoint. Four weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-three mice
were sacrificed and the brains were extracted. GFP-expressing metastases in the brains were
visually identified with a Nikon fluorescent stereomicroscope. There were thirteen mice in the
non-treated control, and ten in each of three groups that received 4 Gy whole-brain irradiation at
different time points with respect to cell injection. The prophylactic cranial irradiation group had
significantly fewer brain metastases than the treatment and pre-irradiation groups (vs. control, p =
0.01; vs. pre-injection, p = 0.0007; vs. treatment, p = 0.07). Surprisingly, pre-irradiation of the
brains caused an increase in the number of mice with brain metastases compared to the control
(100% vs. 77%, p = n.s.). Percentages between groups were compared with Fisher’s exact test.
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Figure 7: Representative Images of Brain and Lung Metastases at Four-Week Endpoint. Four
weeks after tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, fortythree mice were sacrificed and the brains and lungs were extracted. Pictures GFP-expressing metastases
in the organs were taken with a Nikon fluorescent stereomicroscope at 20X magnification. The images
above were created by merging a brightfield photograph of the organ with the GFP expression profile
using the Nikon NIS-Elements software. For the GFP profile, a lower threshold was set so as to
eliminate the autofluorescent background and collect only the emission from metastases.
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Figure 8: Number of Brain Metastases per Mouse at Four-Week Endpoint. Four weeks after
tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-three
mice were sacrificed and the brains were extracted. GFP -expressing metastases in the brains
were visually identified with a Nikon fluorescent stereomicroscope, and the number of brain
metastatic foci per mouse was counted. The different treatment groups had an overall effect on
the number of brain metastases per mouse (p = 0.004), evaluated using the Kruskal-Wallis test.
The prophylactic cranial irradiation group had significantly fewer brain metastases than two of
the other groups (vs. control, p < 0.05; vs. pre-injection, p < 0.01), determined using Dunn’s test.
Horizontal bars represent median and lower/upper quartiles.
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Presence of Lung Metastases: 4-Week Endpoint
0 Gy

10/13

77%

4 Gy WBI @ 2d Pre-injection

9/10

90%

4 Gy WBI @ 5d Post-injection

7/10

70%

4 Gy WBI @ 3wk Post-injection

7/10

70%

Table 4: Presence of Lung Metastases at Four-Week Endpoint. Four weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-three mice
were sacrificed and the lungs were extracted. GFP-expressing metastases in the lungs were
visually identified with a Nikon fluorescent stereomicroscope. There was no significant
difference in the number of mice with lung metastases between the non-treated control and the
three groups that received 4 Gy whole-brain irradiation at different time points with respect to cell
injection. Percentages between groups were compared with Fisher’s exact test.

Presence of Any Metastases: 4-Week Endpoint
0 Gy

12/13

92%

4 Gy WBI @ 2d Pre-injection

10/10

100%

4 Gy WBI @ 5d Post-injection

7/10

70%

4 Gy WBI @ 3wk Post-injection

8/10

80%

Table 5: Presence of Any Metastases at Four-Week Endpoint. Four weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-three mice
were sacrificed and the brains and lungs were extracted. GFP-expressing metastases in the brains
and lungs were visually identified with a Nikon fluorescent stereomicroscope. There was no
significant difference in the number of mice with any metastases between the non-treated control
and the three groups that received 4 Gy whole-brain irradiation at different time points with
respect to cell injection. Percentages between groups were compared with Fisher’s exact test.

Metastases

# Brain+

# Brain-

% Brain+

Lung+

25

8

76%

Lung-

4

6

40%

p = 0.06

Table 6: Association between Brain and Lung Metastases at Four-Week Endpoint.
SCID/Beige mice that had lungs metastases four weeks after tail-vein injection of 0.5 x 106 GFPlabelled MDA-IBC3 cells were more likely to have brain metastases (76%) than the mice that did
not have lung metastases (40%). This result is not significant (p = 0.055), as calculated using
Fisher’s exact test.
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Figure 9: Weight of Mice Sacrificed at Four-Week Endpoint. In each of the four groups, the
weight of mice steadily increased over time until sacrifice. The dotted line represents time of tailvein injection of MDA-IBC3 cells. Error bars not shown.
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B. Eight-Week Endpoint
Fifty-nine to sixty days after tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into
SCID/Beige mice, 45 mice were sacrificed. Of these 45 mice, 10 were non-irradiated controls,
10 were irradiated two days prior to cell injection (pre-irradiation group), 10 were irradiated five
days after cell injection (prophylactic cranial irradiation [PCI] group), 7 were irradiated three
weeks after injection (3-week treatment group), and 8 were irradiated six weeks after injection
(6-week treatment group).
As with the four-week endpoint, the brain and lung tissue was excised in order to
evaluate metastases. Representative images of GFP-positive metastases in brain and lungs eight
weeks after injection are depicted in Figure 10.
The results for the number of mice in each group with brain metastases are shown in
Table 7. Nine out of ten mice in the control group developed brain metastases (90%), greater
than what we observed at four weeks.

Once again, all ten mice in the pre-irradiated group

developed brain metastases, meaning that all twenty mice between the two endpoints that were
irradiated two days prior to injection developed metastases.

In the prophylactic cranial

irradiation group, only three mice developed brain metastases after eight weeks (30%),
consistent both with the results from the four-week endpoint and also with my hypothesis that
PCI would reduce the incidence of brain metastasis.

This was significantly lower than the

incidence of brain metastasis in the four other groups (vs. control, p = 0.02; vs. pre-irradiation
group, p = 0.003; vs. 3-week treatment group, p = 0.009; vs. 6-week treatment group, p = 0.02).
The treatment of mice with 4 Gy WBI at three or six weeks after cell injection had no impact on
the number of mice that developed brain metastases compared to the control, the same result
that we observed at the four-week endpoint.
The number of brain metastases per mouse and the brain metastatic tumor burden per
mouse (as measured in square millimeters from the two-dimensional images) were compared
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between the five different groups (Figures 11 and 12).

Overall, both the number of brain

metastases per mouse (p = 0.0008) and the brain metastatic tumor burden per mouse (p = 0.002)
were significantly affected by the treatments at different time points.

Further, prophylactic

cranial irradiation significantly decreased both number of metastases per mouse and brain
metastatic tumor burden per mouse compared to all of the four other groups ([number of brain
metastases per mouse, PCI: vs. control, p = 0.006; vs. pre-irradiation group, p = 0.02; vs. 3week treatment group, p = 0.004; vs. 6-week treatment group, p = 0.01]; [brain metastatic tumor
burden per mouse, PCI: vs. control, p = 0.01; vs. pre-irradiation group, p = 0.01; vs. 3-week
treatment group, p = 0.04; vs. 6-week treatment group, p = 0.006]).
When the results from the four- and eight-week endpoints were combined (Table 7), the
incidence of brain metastasis was significantly decreased with prophylactic cranial irradiation as
compared to all other groups (vs. control, p = 0.0002; vs. pre-irradiation group, p < 0.0001; vs.
3-week treatment group, p = 0.0008; vs. 6-week treatment group, p = 0.004). The greater
incidence in the pre-irradiation group suggested a trend compared to the 3-week treatment group
(p = 0.08), although no trend was suggested compared to the control (p = 0.11).
Excised lungs from the sacrificed mice were also examined for the presence of
metastases. Because the 4 Gy was administered at various time points only to the brain, we did
not expect to see any differences in the incidence of lung metastasis between the four groups.
However, as Table 9 shows, the mice that received WBI three weeks after cell injection had a
100% incidence of lung metastasis, which was significantly greater than the incidence at three
other time points (vs. control, p < 0.05; vs. pre-irradiation group, p < 0.05; vs. PCI, p < 0.05; vs.
6-week treatment group, p = 0.08).
The different groups were also compared based on the number of mice in each group
that had either lung or brain metastases. As shown in Table 10, the group that received PCI had
significantly fewer metastases than the pre-irradiation and 3-week treatment groups (p < 0.05).
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We expected to see that mice with lung metastases would have a higher incidence of
brain metastasis compared to mice that did not have lung metastases.

The mice with lung

metastases did have a greater incidence of brain metastasis compared to the mice without lung
metastases (92% vs. 65%, p = 0.06), and results suggest a trend (Table 11). When the results
from the four- and eight-week endpoints were combined (Table 12), the difference was
significant (83% vs. 57%, p = 0.01).
The mice steadily gained weight up until five weeks after cell injection, at which point
the average weight in the groups either began to decline or plateau (Figure 13).

Interestingly,

the mice which were irradiated two days before cell injection – those that had 100% incidence
of brain metastasis – saw the sharpest decline in weight loss beginning at six weeks: Of the eight
mice that lost greater than 10% of their body weight from the peak weight, seven were in that
pre-irradiation group (data not shown).

Nevertheless, there was no measured correlation

between the magnitude of weight loss and the brain metastatic tumor burden.

Presence of Brain Metastases: 8-Week Endpoint
0 Gy

9/10

90%

4 Gy WBI @ 2d Pre-injection

10/10

100%

4 Gy WBI @ 5d Post-injection

3/10

30%

4 Gy WBI @ 3wk Post-injection

7/7

100%

4 Gy WBI @ 6wk Post-injection

7/8

88%

p < 0.05
p < 0.01
p < 0.01

p < 0.05

Table 7: Presence of Brain Metastases at Eight-Week Endpoint. Eight weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-five mice were
sacrificed and the brains were extracted. GFP-expressing metastases in the brains were visually
identified with a Nikon fluorescent stereomicroscope. The prophylactic cranial irradiation group
had significantly fewer brain metastases than each of the four other groups (vs. control, p = 0.02;
vs. pre-injection, p = 0.003; vs. 3-week treatment, p = 0.009; vs. 6-week treatment, p = 0.02).
Percentages between groups were compared with Fisher’s exact test.

50

51

Figure 10: Representative Images of Brain and
Lung Metastases at Eight-Week Endpoint.
Eight weeks after tail-vein injection of 0.5 x 106
GFP-labelled MDA-IBC3 cells into SCID/Beige
mice, forty-five mice were sacrificed and the
brains and lungs were extracted. Pictures GFPexpressing metastases in the organs were taken
with a Nikon fluorescent stereomicroscope at 20X
magnification. The images above were created by
merging a brightfield photograph of the organ
with the GFP expression profile using the Nikon
NIS-Elements software. For the GFP profile, a
lower threshold was set so as to eliminate the
autofluorescent background and collect only the
emission from metastases. The brain images on
the previous page are from the control (left) and
pre-irradiation (right) groups; the images on the
current page are from PCI (top left), 3-week
treatment (top right), and 6-week treatment
(bottom left) groups. Metastatic foci from PCI
group visibly smaller.
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Figure 11: Number of Brain Metastases per Mouse at Eight-Week Endpoint. Eight weeks
after tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, fortyfive mice were sacrificed and the brains were extracted. GFP-expressing metastases in the brains
were visually identified with a Nikon fluorescent stereomicroscope, and the number of brain
metastatic foci per mouse was counted. The different treatment groups had an overall effect on
the number of brain metastases per mouse (p = 0.0008), evaluated using the Kruskal-Wallis test.
The prophylactic cranial irradiation group had significantly fewer brain metastases than each of
the four other groups (vs. control, p < 0.01; vs. pre-injection, p < 0.05; vs. 3-week treatment, p <
0.01; vs. 6-week treatment, p < 0.05), determined using Dunn’s test. Horizontal bars represent
median and lower/upper quartiles.
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Figure 12: Brain Metastases Burden per Mouse at Eight-Week Endpoint. Eight weeks after
tail-vein injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-five
mice were sacrificed and the brains were extracted. GFP -expressing metastases in the brains
were visually identified with a Nikon fluorescent stereomicroscope, and the tumor burden per
mouse was evaluated with the Nikon software. The different treatment groups had an overall
effect on the number of brain metastases per mouse (p = 0.002), evaluated using the KruskalWallis test. The prophylactic cranial irradiation group had significantly fewer brain metastases
than each of the four other groups (vs. control, p < 0.05; vs. pre-injection, p < 0.05; vs. 3-week
treatment, p < 0.05; vs. 6-week treatment, p < 0.01), determined using Dunn’s test. Horizontal
bars represent median and lower/upper quartiles.
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Presence of Brain Metastases at Both Endpoints
0 Gy

19/23

83%

4 Gy WBI @ 2d Pre-injection

20/20

100%

4 Gy WBI @ 5d Post-injection

5/20

25%

4 Gy WBI @ 3wk Post-injection

14/17

76%

4 Gy WBI @ 6wk Post-injection

7/8

88%

p < 0.001

p < 0.0001
p < 0.001

p < 0.01

Table 8: Presence of Brain Metastases in Overall Study. Four to eight weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, eighty-eight mice
were sacrificed and the brains were extracted. GFP-expressing metastases in the brains were
visually identified with a Nikon fluorescent stereomicroscope. The prophylactic cranial
irradiation group had significantly fewer brain metastases than each of the four other groups (vs.
control, p = 0.0002; vs. pre-injection, p < 0.0001; vs. 3-week treatment, p = 0.0008; vs. 6-week
treatment, p = 0.004). The pre-irradiation group had a greater incidence of brain metastasis
compared to the group treated with WBI three weeks after cell injection (p = 0.08), suggesting a
trend. There is a non-significant difference between the control and pre-irradiation groups (p =
0.11). Percentages between groups were compared with Fisher’s exact test.

Presence of Lung Metastases: 8-Week Endpoint
0 Gy

5/10

50%

4 Gy WBI @ 2d Pre-injection

5/10

50%

4 Gy WBI@ 5d Post-injection

4/10

40%

4 Gy WBI @ 3wk Post-injection

7/7

100%

4 Gy WBI @ 6wk Post-injection

4/8

50%

*

*

*

*p < 0.05

Table 9: Presence of Lung Metastases at Four-Week Endpoint. Eight weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-five mice were
sacrificed and the lungs were extracted. GFP-expressing metastases in the lungs were visually
identified with a Nikon fluorescent stereomicroscope. The group that received 4 Gy WBRT three
weeks after tail-vein injection had a significantly greater incidence of lung metastasis compared
to three other groups (vs. control, vs. pre-injection, and vs. PCI, p < 0.05). The difference in lung
incidence between 3- and 6-week WBI groups was not significant (p = 0.08). Percentages
between groups were compared with Fisher’s exact test.
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Presence of Any Metastases: 8-Week Endpoint
0 Gy

9/10

90%

4 Gy WBI @ 2d Pre-injection

10/10

100%

4 Gy WBI @ 5d Post-injection

5/10

50%

4 Gy WBI @ 3wk Post-injection

7/7

100%

4 Gy WBI @ 6wk Post-injection

7/8

88%

p < 0.05
p < 0.05

Table 10: Presence of Any Metastases at Eight-Week Endpoint. Eight weeks after tail-vein
injection of 0.5 x 106 GFP-labelled MDA-IBC3 cells into SCID/Beige mice, forty-five mice were
sacrificed and the brains and lungs were extracted. GFP-expressing metastases in the brains and
lungs were visually identified with a Nikon fluorescent stereomicroscope. The PCI group which
was treated with 4 Gy WBI five days post-injection had a significantly lower incidence of
metastasis compared to two other groups (vs. pre-injection and vs. 3-week treatment, p < 0.05).
Percentages between groups were compared with Fisher’s exact test.

Metastases

# Brain+

# Brain-

% Brain+

Lung+

23

2

92%

Lung-

13

7

65%

p = 0.06

Table 11: Association between Brain and Lung Metastases at Eight-Week Endpoint.
SCID/Beige mice that had lungs metastases eight weeks after tail-vein injection of 0.5 x 106 GFPlabelled MDA-IBC3 cells were more likely to have brain metastases (92%) than the mice that did
not have lung metastases (65%). This result is not significant (p = 0.057), as calculated using
Fisher’s exact test.

Metastases

# Brain+

# Brain-

% Brain+

Lung+

48

10

83%

Lung-

17

13

57%

p = 0.01

Table 12: Association between Brain and Lung Metastases in Overall Study. SCID/Beige
mice that had lungs metastases four or eight weeks after tail-vein injection of 0.5 x 106 GFPlabelled MDA-IBC3 cells were significantly more likely to have brain metastases (80%) than the
mice that did not have lung metastases (57%), as calculated using Fisher’s exact test (p = 0.01).
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Figure 13: Weight of Mice Sacrificed at Eight-Week Endpoint. In each of the five groups, the
weight of mice steadily increased up to five weeks after injection. After that, the weight decreased
in the pre-irradiation group, with seven mice losing greater than 10% body weight (four mice were
actually treated and regained the weight, explaining the plateau from days 48-55). In the other four
groups, the weight leveled off five weeks after injection. The dotted line represents time of tail-vein
injection of MDA-IBC3 cells. Error bars not shown.
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SECTION IV. CONCLUSIONS
Prophylactic cranial irradiation is a clinical technique used for patients with SCLC and ALL to
reduce the incidence of brain metastasis. Because of an emerging group of patients at high risk
of developing brain metastasis, PCI is gaining interest as a clinical option for this group.
Through a mouse model of metastatic, HER2+ inflammatory breast cancer, we have
demonstrated that PCI has the potential to benefit these patients, supporting the hypothesis. At
the four- and eight-week endpoints, PCI reduced the incidence of brain metastasis, the number
of metastases per mouse, and the metastatic burden compared to the other endpoints –
significantly in most cases.

There were no significant differences between the other four

groups.
In the original experiment developing this metastatic mouse model [71], two-thirds of
the non-treated SCID/Beige mice injected with MDA-IBC3 cells developed brain metastases at
the eight-week endpoint. Here, 10/13 (77%) mice had developed brain metastases by the fourweek endpoint, and 9/10 by the eight-week endpoint. While the incidence was greater in this
study, it further validates the usefulness of this mouse model as a platform for assessing antibrain metastasis treatments, due to the consistently high incidence in non-treated mice.
The primary endpoint of interest in this in vivo experiment was the incidence of brain
metastasis in the prophylactic cranial irradiation group, which was set as the group of mice
which received 4 Gy whole-brain irradiation five days after cell injection. This time point was
chosen because while cells could be expected to have arrested in the brain by this point, very
few, if any, would have been able to start growing into metastases of appreciable size. We
hypothesized that PCI would reduce the incidence by 50%, and we actually observed a
reduction in incidence compared to the control of 74% and 67% at four and eight weeks,
respectively. Because the effect was present at both four and eight weeks, it is likely that PCI
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has a permanent effect on the incidence of brain metastasis, rather than merely a delay in their
growth.
While the significant reduction in incidence in the PCI group supported the hypothesis, it
was clear from the microscope images that the PCI also had a major effect on the number of
metastases and the metastatic burden. Between the two mice at four weeks and the three mice at
eight weeks that were positive for brain metastases in the PCI group, there were collectively six
brain metastases – six brain metastases among twenty mice. In contrast, there were forty-one
brain metastases among ten mice in the control at eight weeks, and forty-one among thirteen
mice in the control at four weeks.

Further, the metastatic burden at eight weeks was

significantly reduced by PCI compared to the other four groups. This is in part due to the fewer
brain metastases, as burden is a function of number of metastases.

However, the three

metastases that were present in the PCI group were all relatively small. This was not necessarily
expected, as those cells that retained their clonogenic potential after the early irradiation would
still have the full eight weeks to form metastases.
Two groups that were irradiated three and six weeks post-injection were included in the
study to serve as something akin to positive controls, in that the presence of brain metastases
would already be expected by the time these mice were irradiated.

It was necessary to

distinguish between prevention and treatment, so these two groups were labelled as the latter.
Unsurprisingly, there were no significant differences between the non-irradiated control and the
two treatment groups when considering the endpoints of incidence of brain metastasis and the
number of brain metastases per mouse. However, there were also no significant differences in
tumor burden. While a dose of 4 Gy would not be expected to eradicate all clonogenic cells in
the two treatment groups, and thus would not affect incidence and number of metastases, it
could be expected to decrease the average volume of metastases through cell kill. This would
be reflected by the metastatic burden, but it seems that the 4 Gy dose had negligible effect on
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metastatic volumes compared to the non-irradiated control. A couple of possible explanations
center around hypoxia and accelerated repopulation, and will be discussed later
Last, a group of mice was irradiated two days prior to cell injection as an attempt to
control for any effects that radiation has on the local microenvironment apart from any effects
on the tumor cells themselves.

Interestingly, the incidence of brain metastasis in this group at

both the four- and eight-week endpoints was 100%.

Although not a significant difference

compared to the non-irradiated control, this taken alone could be suggestive of “priming” of the
brain for the growth of metastases. Further, in the group of mice that was pre-irradiated for the
eight-week endpoint, there was a sharp decrease in the average mouse weight, possibly
indicating greater metastatic burden.
There have been studies looking at the effect of pre-irradiation of host tissues on
malignant

growth:

Barcellos-Hoff and

collaborators

[115]

found

that

non-transformed

mammary epithelial cells preferentially formed tumors in cleared mammary fat pads that were
pre-irradiated with 4 Gy (81% vs. 19% incidence). Conversely, the tumor bed effect describes
the phenomenon whereby experimental tumors grow slower in pre-irradiated tissues [117]. In
the PCI experiment, there was a negligible difference between the number of metastases per
mouse and the metastatic burden; therefore, the data does not support the hypothesis that
radiation primes the brain for metastatic growth.

Also, no connection was observed between

weight loss and any of the experimental endpoints.
A sub-aim of the study was to evaluate any correlation between lung and brain
metastases, and here there was a significant association between the incidence of lung and brain
metastasis.

One question this raises is whether many of the brain metastases are secondary

metastases, with the lungs as the primary metastatic site. This seems unlikely, however, as the
PCI would not have as much of an effect if many of the disseminated tumor cells arrived in the
brain via the lungs after the day of irradiation (i.e. five days post-injection).
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Similarly, the

incidence in lung and brain metastasis appears independent when breaking down the mice into
the five experimental groups: PCI had a clear effect on the incidence of brain metastasis, but the
incidence of lung metastasis in the PCI group was the same as in the other experimental groups.

As mentioned above, this experiment helps validate the utility of this metastatic mouse model,
as not only is the incidence of brain metastasis consistently high in untreated

mice, but also

experimental treatments clearly are able to show an effect. Likewise, the PCI study validates
the small-animal irradiator as an experimental apparatus, as the treatment delivered to the mice
was consistent and was able to produce data of clinical relevance.
While the experimental system used in this study was unique and robust, it was not
without limitations, especially in the context of the clinical question regarding PCI. First, there
was a single day of tail-vein injections of 500,000 GFP-labelled, MDA-IBC3 cells. This does
not accurately represent the shedding of breast cancer cells/clumps into the circulation in
patients, which likely happens gradually as long as the primary tumor is present, providing a
constant source of new circulating tumor cells. A more clinically relevant mouse model would
involve spontaneous metastases arising from a primary breast tumor, but no adequate
spontaneous metastases models exist.

In the clinical situation, the distribution of volumes

would be log-normal, as a function of both different growth rates and different times at which
point the metastatic site was colonized [118]. In the PCI experiment, the growth rates clearly
differ due to the variation in the size of metastases, but all start growing in the same general
time frame.

Further, there is evidence suggesting that metastases are seeded by clumps rather

than single cells [119]; because this is not a spontaneous model, this could not be simulated.
A second limitation of the PCI experiment is that a single dose of 4 Gy was delivered on
a single day to each of the treated mice. The clinical scenario for humans would involve several
fractions of a much higher dose – for example, 10 fractions of 2.5 Gy each. Also, the single
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fraction used in the experiment was for simplicity. A more clinically appropriate scenario might
involve five fractions of 1 Gy in mice, or something similar.

The combination of a single

injection point and a single time of irradiation likely leads to an overestimation of the impact
that timing has on the experimental endpoints.
A third limitation involves the primary experimental endpoint chosen – incidence of
brain metastasis – and how it differs from the major clinical endpoint – overall survival. While
the goal of PCI in the clinic is to directly reduce the incidence of brain metastasis, it would not
be beneficial unless it also increased overall survival.

In our PCI experiment, we could not

monitor the presence of metastases in vivo, and consequently we had to sacrifice the mice to
evaluate the metastatic burden.

A possible future direction would be to conduct the same

experiment, but then evaluate the mice for survival; however, this might not be effective unless
the entire disease process could be simulated – controlled extracranial disease with
chemotherapy and/or Trastuzumab.
A final limitation is that the experiment only tests the effect of PCI on one breast cancer
cell line, which does not represent the entire high-risk breast cancer patient cohort.

Future

experiments could involve the use of other cell lines such as triple-negative breast cancer cell
lines.

A next step from this study is to consider what a PCI clinical trial could look like in breast
cancer patients at high risk of developing brain metastases; however, I will withhold this
conversation until the general discussion. I will mention here that the importance of the timing
of PCI has been evaluated before in the case of small cell lung cancer.

Withers and

collaborators [120] conducted a meta-analysis of clinical trials, focusing on the reduction in
incidence of brain metastasis compared to the control as a function of both radiation dose and
when the radiation was administered with respect to the completion of chemotherapy.
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They

found that “early” PCI was more effective than “late” PCI, where the delay actually introduced
a dose threshold below which the incidence of brain metastasis was unchanged compared to the
control. Because of these results from the SCLC PCI study, and from the significant effect that
PCI had in our mouse model of metastatic breast cancer, we wanted to explore more thoroughly
how sensitive the experimental endpoints are to the timing of whole-brain irradiation; rather
than performing additional mouse studies, I opted to develop a computational model of our
experimental system.
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CHAPTER 3: MATHEMATICAL MODELING OF SUBCLINICAL
BREAST CANCER BRAIN METASTASIS DOSE RESPONSE
SECTION I. INTRODUCTION
The experimental results from the in vivo prophylactic cranial irradiation experiment supported
the hypothesis that PCI would reduce the incidence of brain metastasis in our mouse model.
However, the magnitude of the decrease and the overall effect of PCI on the number of the
metastases and metastatic burden was surprising. The effect of PCI – irradiation administered
five days after cell injection – stood in sharp contrast to the effect of the whole-brain irradiation
administered at either three or six weeks after cell injection.

Because of this, we wanted to

expand on the experimental results, connecting the radiation time points in order to explore how
much of the difference between experimental groups could be attributed to a volume effect – i.e.
larger tumors require greater dose because more cells must be inactivated.

Further, mapping

how the experimental endpoints such as incidence change over time could inform the period
where PCI might be most effective. Rather than repeating the in vivo experiment with different
radiation time points, I have developed a computational model that accurately mimics the
experimental results and can be used to increase our knowledge about the radiation dose
response of subclinical breast cancer.
In general, computational models are useful as they can incorporate information from
different sources into a coherent framework in order to better understand biological processes.
Often, they can elucidate the dynamics of a system, and can indicate which might be the most
sensitive parameters (e.g. radiation dose, timing) [121]. In this case, information from both our
in vivo PCI experiment and in vitro mammosphere and clonogenic assays, as well as
assumptions about tumor growth kinetics, were drawn upon in order to better understand how
radiation affects the incidence and number of brain metastases in our mouse model of HER2+,
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inflammatory breast cancer.

To the best of our knowledge, this is the first attempt to

mathematically model subclinical disease radiation dose-response.
The second and third aims will both be addressed in this chapter. The second aim is to
develop a computational model of radiation dose-response for subclinical breast cancer based
on the metastatic HER2+ mouse model. The sub-aims are to recapitulate the experimental nonirradiated mice data by optimizing input parameters and to validate the model assumptions and
inputs by performing a limiting dilution assay.
The third aim is to demonstrate that 4 Gy prophylactic cranial irradiation in the
computational model reduces the incidence of brain metastasis by 50%. The sub-aims are to
investigate if the experimental incidence can be explained by the assumptions used to develop
the model and to demonstrate that delaying treatment introduces a dose threshold below which
no reduction in the incidence is observed.
In developing this computational model, several trade-offs were made. Perhaps the most
important involved simplicity vs. information: models should be built on robust experimental
data, but including too much information has the potential to dilute the effect of what is most
important [121].

For this mathematical model, simplicity was generally favored, in that the

foundation of the model is derived primarily from the experimental data, and as few
assumptions as possible are made in order to describe metastatic growth. Further, extraneous
biological phenomena such as tumor heterogeneity are ignored, in part because of a lack of
robust experimental data, and also because incorporating such information would require more
assumptions. In this sense, the model is as physical (as opposed to biological) as possible.
The computational model discussed here is descriptive, rather than mechanistic, in
nature. In other words, the focus is on how individual cells grow into metastases and then how
the mass of cells respond to radiation in binary terms of life or death.
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The smallest unit

described here is the single cell, so the underlying mechanisms of colonization biology or DNA
damage response, for example, are not considered.
Underlying biological processes are governed in large part by randomness, and I have
attempted to incorporate that randomness into this mathematical model. In this sense, the model
is stochastic when sample sizes are on the order of experimental sample sizes (ten mice per
group in this case).

However, mathematical modeling affords us the opportunity to run

simulations on a much larger sample than would be feasible experimentally. Consequently, the
model acts deterministically for large sample inputs, as the inherent randomness is averaged out
and a “true” mean is approached.

In this study, one thousand simulations (i.e. one thousand

mice) were conducted to acquire each data point.
After running several simulations, the experimental endpoints of incidence of brain
metastasis, number of brain metastases per mouse, and brain metastatic burden from the
irradiated groups were compared to the computational model output of the same endpoints.
This is possible because the experimental results from only the non-irradiated control mice are
used to actually develop the model. Predictions regarding the effect of radiation on cell survival
are derived largely from in vitro clonogenic data (unpublished).

If the computational model

output diverges from the experimental results, then the magnitude of that difference becomes
important: If small, then the difference could likely be explained by imperfect assumptions that
are made in the development of the model; if large, then there may be underlying causes not
incorporated into the model, and hypotheses could be generated in an attempt to explain the gap.
Developing this computational model carries other benefits that are not directly related
to the PCI experiment. For instance, it could help inform what time period after injection that
future experimental treatments should be delivered.

Additionally, knowing the effect of

different survival fractions on the experimental endpoints could serve as a starting point for
selecting an appropriate experimental sample size.
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SECTION II. METHODOLOGY
A. Conceptualization of Model

Figure 14: Overview of Development, Execution, and Evaluation of Model. See text for details.

In order to develop a computational model, experimental data from one or more sources must be
combined with a set of assumptions. In this case, the experimental data available is the number
of metastases per mouse, and the area of each metastasis, from both the non-irradiated and the
irradiated mice.

Because one goal is to test if the computational model can recapitulate the

dose-response results from the PCI experiment, the irradiated mouse data cannot actually be
used to develop the model, but only as a comparison against which the model output is
evaluated.

Therefore, only the non-irradiated mouse data was used in the development of the

computational model.
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Because of the limited experimental data (10-13 data points for number of metastases
per mouse; 40 data points for area of metastases), the data was fit to normal or log-normal
curves. This allows for a larger distribution of data in the development of the model which still
reflects the experimental results.
From the areas of individual metastases from the microscope images, the volumes are
estimated, and from that the number of cells in each metastasis. Assuming the area is the largest
cross-section of a spherical metastasis, the area is converted into a radius (A = πr 2 ) and then into
a volume (V = 4/3*πr3 ).

Throughout the model, one cubic millimeter corresponds to one

million cells, and one cubic centimeter corresponds to one billion cells.
Because I have volume data from two time points, at four and eight weeks after
injection, I can actually solve for the parameters in the Gompertz equation (two equations, two
unknowns) by making an assumption about when the cells begin to proliferate in the brain. This
will provide a distribution of Gompertz parameters that will be used to define the growth of the
metastases.
Next, it is assumed that the probability that a disseminated breast cancer cell in the brain
can form a metastasis (metastasis-formation efficiency) is equal to the mammosphere-formation
efficiency from our in vitro studies. Again, this will be a distribution of probabilities rather than
a single value.
Working backwards, it was then possible to approximate the number of disseminated
breast cancer cells in the brain soon after cell injection by running the model and comparing the
output to the aforementioned normal fit of the experimental number of metastases per mouse.
Once the model inputs have been optimized and validated, then radiation can be implemented
and compared to the experimental irradiated groups.
All of this is discussed in more detail below, but first I will list the assumptions made in
the development of the computational model.
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Key Assumptions:


The model was developed using only the raw data from the non-irradiated control group
from the four- and eight-week endpoints. This is considered the “training” set.



The brain is seeded exclusively by single breast cancer cells, as opposed to clumps, and
all metastases arise from those single cells



The metastases are perfect spheres



The raw microscope images provide an area for each metastatic focus: from this area an
effective radius is calculated, which is converted to a volume of the metastatic sphere



The effect of scatter on metastasis area on the microscope images is ignored



Growth of metastases is governed by Gompertzian kinetics



The distribution of experimental metastatic volumes is best approximated by a lognormal curve



The distribution of the experimental number of metastases per mouse is best
approximated by a normal curve



The threshold for detection of metastases, from both the experiment and the model, is 50
cells. Metastases with fewer cells than this are not “counted.”



The four- and eight-week endpoint mice were injected with cells on two different days.
It is assumed that those cells injected were the same on both days



Once the cells start proliferating, they continue to proliferate up to the eight-week
endpoint without stopping; any four-week volume can lead to any eight-week volume,
within limits set by the Gompertz equation



Although each mouse was an independent observation, the success of PCI depends on
eradication of individual metastases; therefore, in this model it is assumed that each
metastasis is the individual measurement.
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When radiation is administered, all cells that die do so immediately, without further
proliferation



Each metastasis will have an upper growth limit defined by parameters in the Gompertz
equation. Cell kill due to irradiation will not alter this upper growth limit.



After a tumor is irradiated, each surviving cell has the ability to continue proliferating in
an attempt to repopulate the tumor



Hypoxia: the outer 100 microns of each metastasis is fully oxygenated, while the core (if
applicable) is hypoxic, with an oxygen enhancement ratio of 3.0



Apart from hypoxia, all cells that can form a metastasis are equivalent



All cells that could form a metastasis will have done so by the eight-week endpoint in
the non-irradiated condition



All breast cancer cells that would arrest in the brain would do so by 3 days post-injection



~35% of metastases that would be present at the eight-week endpoint will be below the
threshold for detection (50 cells) at the four-week endpoint, in the non-irradiated group

B. Fitting Experimental Data to Distributions
From the PCI in vivo experiment, there are two endpoints at four and eight weeks post-injection.
At the four-week endpoint, there is data from thirteen mice: thirteen data points for number of
metastases per mouse, and forty-one data points for the volumes of individual metastases. At
the eight-week endpoint there is data from ten mice: ten data points for number of metastases
per mouse and forty-one data points for the volumes of individual metastases.
The number of metastases per mouse data from both time points was fit to a Gaussian
probability distribution, using both quantitative correlation and qualitative evaluation (i.e. if this
experiment was performed 100 times, would it be reasonable to expect a distribution like this?).
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The volume of individual metastases data from both time points was fit to a log-normal
probability distribution (log-normal = taking the logarithm of the volumes, and then fit that to a
Gaussian) using quantitative correlation. A modification was made to the fit from the four-week
time point in order to accommodate the assumption that 35% of eventual metastases are not
observable at that time.

C. Generation of Gompertz Parameters
It is assumed that the growth of metastases is governed by Gompertzian kinetics. Here is the
Gompertz equation, where N is the number of cells, t is the time, and A & B are parameters:

A
N = N0 ∗ exp [ ( ) ∗ ( 1 − exp[−B ∗ t] ) ]
B
One can see that at t = 0, the equation reduces to N = N0 * exp(0) = N 0 . N 0 here is 1 cell, from
which all metastases are assumed to grow. When t approaches infinity, N = N0 * exp(A/B),
which is the asymptote defining the upper limit of growth.

When B is very small, then the

growth is approximated by a pure exponential: N = N0 * exp(At).
Notice that there are two parameters with unknown values, A & B.

It is actually

possible to solve for these parameters using a system of two equations: one from each time point
relating the number of cells and time interval since the start of cell proliferation, which is
assumed to be ten days. In order to determine which sets of equations to use (i.e. which volume
at four weeks and which volume at eight weeks to use in the system of equation to calculate one
A & B pair), an assumption was made that the any volume at four weeks (from the log-normal
curve) could pair with any volume at eight weeks, within the limits of the Gompertz equation.
Thus, a distribution of A & B was created based on the log-normal fits of the experimental
volumes. These parameters then define the growth of the metastases in the model such that it
reflects the experimental volume information.
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D. Workflow of Model
Here, the basic operation of the model is described.

Inputs:


Average number of disseminated tumor cells in the brain



Average metastasis- formation efficiency of cells



Average interval between cell injection and start of cellular proliferation



Day when radiation is administered, if applicable



Average survival fraction after irradiation, if applicable

Each input, except for day of irradiation, will also have a standard deviation

The metastasis-formation efficiency was extracted directly from the mammosphere-formation
efficiency observed in previous in vitro work. The number of disseminated tumor cells in the
brain and the average interval between cell injection and the start of proliferation were both
defined during the optimization process (next section). The day of the radiation and the survival
fraction are both selected by the user in order to test a hypothesis.

Model:


Look at each mouse brain
o How many disseminated tumor cells are in the brain?
o Of those, how many can form a metastasis?
o Look at each disseminated tumor cell that can form a metastasis in that brain


When does the cell start proliferating?



What are the parameters for Gompertzian growth?



What is the surviving fraction after irradiation?



How many cells are there each day (i.e. volume) from days 1-56?
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Each question is answered by drawing randomly from an input distribution or via calculation.
Outputs:


Incidence of brain metastasis at four and eight weeks post-injection



Number of metastases per mouse at four and eight weeks



Volumes of metastases at four and eight weeks



Tumor burden of individual mice at eight weeks

The outputs in the model correspond to the outputs from the PCI experiment, so that a
comparison can be made where appropriate.

E. Optimization of Model
At this stage, the model has been developed but the inputs have not been optimized to
correspond to the experimental data. While the log-normal fit of the experimental volumes was
to generate a distribution of Gompertz parameter pairs, the normal fit of the experimental
number of metastases per mouse is used here to optimize the inputs of: the number of
disseminated tumor cells (DTCs) in the brain after injection and the average interval between
cell injection and the start of cellular proliferation. Note that the input of metastasis-formation
efficiency is fixed based on in vitro experimental work; however, the product of metastasisformation efficiency and the number of DTCs generates the same output over a large range.
The two input distributions (normally distributed: mean and standard deviation are both
inputs) were modified until the model output and the experimental number of metastases per
mouse were highly correlated.
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F. Validation of Model: Limiting Dilution Assay
After the model inputs were optimized, a method of independent validation was sought.

In

order to accomplish this, a limiting dilution assay was performed, in which different numbers of
cells (dilutions) were injected in the tail-vein of SCID/Beige mice, and the incidence of brain
metastasis was evaluated. The experimental conditions were the same as those used in the PCI
experiment: same cell line, same mouse strain, same endpoint, etc.
There were five different groups: ten mice with 500k cells (same as PCI experiment and
assumed as the number of injected cells in the computational model), ten mice with 250k, ten
mice with 50k, ten mice with 5k, and five mice with 500 cells. To represent the dilution in the
model, the number of disseminated tumor cells and its associated standard deviation was scaled
accordingly.

The experimental incidence of brain metastasis was then compared against the

model output.

G. Execution of Model: Comparison of Model Output to Experimental Results
Having developed, optimized, and validated the model, the hypothesis could then be tested by
“administering” radiation to the model.

This was done by selecting a series of time points at

which the radiation is delivered, and at each time point looking at a range of survival fractions,
which correspond to doses based on in vitro data.
Irradiation was administered on the following days (experimental time points in bold):
3

5

7

9

11

14

17

21

27

35

42

49

55

Survival fractions used at different days of irradiation (bold values always used):
1.0

0.75

0.5

0.35

0.25

0.15

0.10

0.05

0.025

0.01

0.005 0.0025 0.001

Specific combinations correspond to specific questions, as discussed in the results section.
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SECTION III. RESULTS
Fitting Experimental Data to Distributions
The volumes of individual metastases and the number of metastases per mouse were fit to lognormal and normal distributions, respectively.

The Gaussian fits of the number of metastases

per mouse are shown in Figures 15 and 16. The correlation between the four-week endpoint
data and the fit was 87%, and the correlation at eight weeks was 66%. In the case of the eightweek endpoint, a significant amount of correlation was “sacrificed” in order to achieve a more
reasonable probability distribution (i.e. the peak at n = 3 is represented by the fit, but it is not
overemphasized, which would have actually improved the correlation to 75-80%).

The mean

and standard deviation was 0.0 and 4.0, respectively, at the four-week endpoint; and 3.2 and 3.0,
respectively, at the eight-week endpoint. The lower cutoff was zero.

Figure 15: Gaussian Fit of Number of Metastases per Mouse at Four-Week Endpoint. A Gaussian
curve (blue line) was fit to the experimental probability distribution (histogram) from the non-irradiated
group, using both quantitative and qualitative methods. The correlation between the fit and the
experimental data is 0.87. The fit has a mean of 0.0 and a standard deviation of 4.0, with a lower cutoff
at zero. This fit was used to optimize the model inputs.
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Figure 16: Gaussian Fit of Number of Metastases per Mouse at Eight-Week Endpoint. A Gaussian
curve (blue line) was fit to the experimental probability distribution (histogram) from the non-irradiated
group, using both quantitative and qualitative methods. The correlation between the fit and the
experimental data is 0.66. The fit has a mean of 3.2 and a standard deviation of 3.0, with a lower cutoff
at zero. This fit was used to optimize the model inputs.

The fits for the number of metastases per mouse were not used in the development of the
model, but rather as a comparison to model outputs in order to optimize model input.

The

optimization results are described below and shown in Figures 19 and 20.
The volumes of individual metastases at the four- and eight-week endpoints were fit to
log-normal distributions (Figure 17). The red circles represent the experimental data points, the
x-axis shows the log-base 10 of the number of cells (i.e. volume [mm3 ] * 106 ), and the y-axis
simply represents the cumulative probability of the number of cells.

Remember that the

volumes were generated from the areas of the metastases on the microscope images, assuming
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the metastases are perfect spheres. The correlation between the fit and the experimental data
was 97.6% at four weeks, and 97.1% at eight weeks.
An assumption was made, based on the number of metastases per mouse data, that 35%
of total metastases would go unobserved at the four-week endpoint (Figure 17, tan box at
origin).

Therefore, this needed to be represented by the volume data, where 50 cells is the

detection threshold (log-value of 1.7). This caused a slight decrease on the goodness of fit. The
volume information was used to define the Gompertzian growth kinetics (next section).

Generation of Gompertz Parameters
As a reminder, here is the Gompertz equation:

A
N = N0 ∗ exp [ ( ) ∗ ( 1 − exp[−B ∗ t] ) ]
B
Again, N represents the number of cells, which is known by converting the volumes from the
microscope images (area  volume  number of cells).

The time since the start of cell

proliferation is given by t, and A & B are the Gompertz parameters that can be solved with a
system of two equations based on the two volume fits.
For each pair of volumes, B and then A were calculated.

For smaller tumors, the

parameter B is essentially zero, meaning that the metastatic focus grows exponentially.

The

larger the tumor is to become, the more the growth slows over time. This distribution of B is
generated in the model, and each disseminated tumor cell in the brain that is to become a
metastasis will randomly draw a value of B from this distribution to define its growth
parameters. The range of possible metastatic growth curves is shown in Figure 18.
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Figure 17: Log-Normal Fit of Experimental Volumes . In order to define the range of growth
parameters that will be stored in the model, the experimental volumes of the metastases from the fourand eight-week endpoints (red circles) were fit a log-normal curves (blue lines). The correlation was
over 97% for both fits. The green box at the bottom left indicates the range of volumes at the four-week
endpoint that were below the threshold for detection. Based on the total number of metastases among the
non-irradiated mice at four and eight weeks, it was assumed that 35% of metastases are below that
threshold (here, -4.3 corresponds to 50 cells). In this region, the curve was modified so that the fourweek volumes are consistent with the eight-week volumes in the pure exponential growth condition.
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Figure 18: Metastases Growth Curves . Based on the Gompertz parameters, the range of possible
growth is shown, assuming proliferations starts ten days post-injection. Note the bunching of volumes at
four and eight weeks at the intermediate values, recapitulating the log-normal volume distribution.

Optimization of Model
Once the distribution of Gompertz parameters was generated, the model was optimized by
modifying two input parameters.

As a reminder, the three principal inputs are the number of

breast disseminated tumor cells (DTCs) in the brain shortly after injection, the metastasisformation efficiency, and the average interval between cell injection and the start of cell
proliferation.
The metastasis-formation efficiency was set at 2.2% (0.5%), taken directly from in vitro
mammosphere-formation efficiency data.

This was done mostly for simplicity: the product of
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DTCs in the brain and metastasis-formation efficiency gives the expected number of metastases
in the brain, so adjusting one of those parameters is enough to optimize the model.
From the experimental data, the average number of metastases per mouse at the eightweek endpoint (when all metastases are assumed to be observable) was between 3.5 and 4.0.
Using this information, it seemed reasonable to estimate that the average number of DTCs in the
brain was 160-180 (3.5/0.022 = 160). This was the starting range for the optimization. The
standard deviation was more difficult to determine, but was in effect the parameter that defined
the variability in the model output of number of metastases per mouse. For example, a narrow
standard deviation would give an average of 3.5-4.0 metastases per mouse, but with a tight
range. The optimized inputs were determined to be 160 DTCs with a standard deviation of 60
cells. This led to excellent coverage of the number of metastases per mouse (Figure 19).
For the interval between cell injection and cell proliferation, the experimental volumes
and their associated log-normal fits gave a few hints.

Based on the greater deceleration of

growth among the relatively large metastases, and the mostly exponential growth among the
medium and smaller metastases, it seemed that proliferation started somewhere between five
and fifteen days after cell injection. From this, an average interval of ten days was selected with
a standard deviation of three days.
The optimized input parameters were those which gave the best correlation between the
Gaussian distribution of the number of metastases per mouse (from Figures 15 and 16,
corresponding to the four- and eight-week endpoints) and the model output of the same
endpoint. With the optimized input parameters described above, the correlation was 95.7% at
the four-week time point and 98.2% at the (more important) eight-week time point (Figure 20).

80

81

Figure 19: Optimized Input Distributions . The three input parameters to the computational model
were optimized by comparing model output to the Gaussian fit at the four- and eight-week endpoint (see
Figures 15 and 16). The chosen parameters were 160 disseminated breast cancer cells in the brain
shortly after injection, with a standard deviation of 60 cells (previous); a metastasis-formation efficiency
of 2.2%, with a standard deviation of 0.5% (previous); and an average interval of 10 days between cell
injection and the day when a given disseminated tumor cell in the brain begins to proliferate, with a
standard deviation of 3 days (above). The metastasis-formation efficiency was extracted from
mammosphere-formation efficiency experiments conducted with the same cell line that was used in the
PCI experiment.
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Figure 20: Comparison of Experimental Gaussian Fit to Model Output. The generation of the
Gaussian fits were described above (Figures 15 and 16). When the optimized parameters (Figure 19)
were input to the model, the model output (histogram) was highly correlated to the fit of the experimental
data. Four the four-week endpoint, the correlation was 95.7%, and at eight weeks, the correlation was
98.2%.
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Validation of Model: Limiting Dilution Assay
In order to help independently validate the computational model, a limiting dilution assay was
performed.

When five-hundred thousand MDA-IBC3 cells were injected into the tail vein of

SCID/Beige mice, as in the PCI experiment, the incidence was 100%. When only five thousand
cells were injected, the incidence was zero (see table below).
To account for the different cell dilutions in the computational model, the number of
DTCs was scaled down linearly from 160 (e.g. for 50,000 injected cells, input was 16 DTCs
with standard deviation of 6 DTCs).

The correlation between the experimental incidence of

brain metastasis and the model output was excellent, indicating that the optimized input
parameters are appropriate.

# Cells Injected

Incidence

500,000

10/10

250,000

9/10

50,000
5,000

3/10
0/10

500

0/5

Figure 21: Validation of Computational Model. In order to help validate the model, a limiting dilution
assay was performed, in which different numbers of MDA-IBC3 breast cancer cells were injected into
the tail vein of SCID/Beige mice. The incidence of brain metastasis in this study is shown by the blue
line at 5 data points. To predict the effect of different numbers of injected breast cancer cells, the model
input of average (standard deviation) number of disseminated breast cancer cells (Figure 19) was scaled
linearly, and the results are shown by the red line. The correlation between the experiment and the
model was approximately 100%.
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Execution of Model: Comparison of Model Output to Experimental Results
In order to compare the model output to the experimental results in the irradiated groups, and
also to expand on those results, simulations of the model were run for different days of radiation
administration and different survival fractions (i.e. different doses).

For each radiation day-

survival fraction combination, n = 1000 mice was used.
The major experimental endpoints that were evaluated in the computational model were
incidence of brain metastasis, average number of metastases per mouse, and metastatic burden
(sum of volumes in each brain). These comparisons are shown in Figures 22, 23, and 24. In
each of these figures, each line represents a single survival fraction in the computational model,
where the different radiation time points are connected.

The vertical dotted lines show the

radiation time points that correspond to the experiment (PCI group: 5 days; 3-week treatment
group: 21 days; 6-week treatment group: 42 days). The large red circles on the dotted lines
show the experimental data for these radiation time points, while the large red circles adjacent to
the y-axis indicate the non-irradiated control experimental results.
For the incidence of brain metastasis (Figure 22), the computational model makes clear
that the selected survival fractions make a significant difference only when the radiation is
administered early.

After about three weeks, the difference in incidence between the non-

irradiated control and 90% cell kill is predicted to be negligible. A similar trend is observed for
the average number of metastases per mouse (Figure 23), where the survival fractions become
insignificant after 4-5 weeks. For both the incidence and the average number of metastases, the
experimental results from the PCI group correspond to a 10% survival fraction in the
computational model, whereas the two later treatment groups are indistinguishable from the
non-irradiated control.
Because metastatic burdens varies widely, even on a logarithmic scale, the model output
and experimental results are presented as upper quartile, median, and lower quartile in Figure
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24. The computational model recapitulates the burden in the non-irradiated control, while the 3and 6-week treatment groups, while varying greatly, are not distinguishable from 100%
survival.

On the other hand, the PCI group is again consistent with a 10% survival fraction.

Note that the model predicts zero tumor burden as a median and lower quartile in the 10%
survival fraction condition when the radiation is administered five days post-injection.

This is

indicated by the red circles appearing below the x-axis. The model output also shows that the
median for 10% survival and the lower quartiles for 10% and 25% survival dips below a logvalue of -4: in these cases, the values actually drop to zero tumor burden.

Figure 22: Incidence of Brain Metastasis at Eight-Week Endpoint. When whole-brain irradiation is
administered in the few weeks after cell injection, the computational model predicts that the decrease in
incidence of brain metastasis compared to the non-irradiated control is very sensitive to both survival
fraction and day of irradiation. The dotted lines represent the experimental radiation time points, and the
red circles indicate the incidence at those time points (The red circle at the y-axis indicates that the model
accurately reflects the incidence in the non-irradiated control.). The incidence in the PCI experimental
group is consistent with a 10% survival fraction, whereas the 3- and 6-week treatment groups could be
represented by 10-100% survival, due to the insensitivity of dose on the incidence at those times.
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Figure 23: Number of Brain Metastases per Mouse at Eight-Week Endpoint. When whole-brain
irradiation is administered in the few weeks after cell injection, the computational model predicts that the
decrease in the average number of brain metastases compared to the non-irradiated control is very
sensitive to both survival fraction and day of irradiation. The dotted lines represent the experimental
radiation time points, and the red circles indicate the incidence at those time points (The red circle at the
y-axis indicates that the model slightly underestimates the average number of brain metastases per mouse
in the non-irradiated control.). There are two red circles at 21 days to represent both the mean and the
median. The number of metastases per mouse in the PCI experimental group is consistent with a 10%
survival fraction, whereas the 3- and 6-week treatment groups are consistent with 100% survival.
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Figure 24: Tumor Burden at Eight-Week
Endpoint.
When whole-brain irradiation is
administered in the few weeks after cell injection,
the computational model predicts that the
decrease in the metastatic burden is very timesensitive when the majority of cells are killed.
The effect is less pronounced at later time points,
where the burden changes little with respect to
time. The dotted lines represent the experimental
radiation time points, and the red circles indicate
the incidence at those time points. A lower cutoff
of -4 (100 cells) was chosen, and the lines below
that threshold indicate zero burden.
The
experimental data points (red circles) below the
axis indicate zero burden, and the one point
above the axis indicates a burden greater than the
upper threshold of the graph. The burden in the
PCI experimental group is consistent with an
approximately 10% survival fraction, whereas the
3- and 6-week treatment groups cannot be
distinguished from the non-irradiated condition.
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Model Predicts Treatment Delay-Induced Dose-Threshold Effect
Different conclusions can be drawn if the effect of radiation timing is plotted against survival
fraction, independent of the experimental results.

Figures 25 and 26 show the reduction in

incidence and the reduction in the average number of metastases per mouse, respectively,
compared to the non-irradiated control. This is displayed for four different radiation time points
– days 5, 9, 14, and 21 – and is plotted as a function of survival fraction.
In Figure 25, it is apparent that delaying the whole-brain irradiation introduces a dosethreshold effect, in which a reduction in the incidence of brain metastasis is not observed until a
sufficiently low survival fraction (i.e. a sufficiently high radiation dose).

In the case of the

whole-brain irradiation being administered at twenty one days after cell injection, that threshold
appears to correspond to a 10-15% survival fraction. In contrast, a 10-15% survival fraction
reduces the incidence of brain metastasis by well over 50% when the dose is administered five
days post-injection.
A similar effect is shown in Figure 26, where the reduction in the number of metastases
decreases linearly with increasing cell kill (this is intuitive) for early radiation time points, but a
dose-threshold is apparent for the twenty-one day irradiation. In this case, the reduction in the
number of metastases is not observed until at least 65% cell kill, at which point over 50%
reduction would be observed in the five-day irradiation condition.
Extrapolating the fraction cells killed in Figure 25 into a radiation dose can make the
information more clinically meaningful.

The conversion is done via in vitro monolayer

clonogenic data (not shown), from which it is assumed that there is an inverse log-linear
relationship between radaition dose and survival fraction (i.e. 8 Gy gives 10% survival, 16 Gy
gives 1% survival, etc.). The result is shown in Figure 27, where the dose threshold seems to be
about 6 Gy.

Again, a similar effect would be observed with the number of metastases per

mouse data, but this is not shown here.
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Figure 25: Reduction in Incidence compared to Non-Irradiated Control. The reduction in the
incidence of brain metastasis at the eight-week time point is plotted against the fraction of cells killed for
four different days of irradiation. The sooner the radiation is administered, the greater the reduction of
incidence. The extreme cases, days 5 and 21, represent days of administration in the PCI experiment.
The delay of irradiation introduces a dose threshold before which the incidence is reduced: in this case,
administering radiation twenty-one days after cell injection would require approximately 90% cell kill
(dotted vertical line) before a reduction in the incidence is observed. At this survival fraction, the
reduction in incidence caused by radiation delivered five days after cell injection is well over 50%.
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Figure 26: Reduction in Number of Metastases compared to Non-Irradiated Control. The
reduction in the number of brain metastases at the eight-week time point is plotted against the fraction of
cells killed for four different days of irradiation. The sooner the radiation is administered, the fewer the
number of metastases that form. The extreme cases, days 5 and 21, represent days of administration in
the PCI experiment. Similar to the reduction in incidence in the previous figure, there appears to be a
dose threshold before a reduction in the number of metastases is observed. The dose threshold
corresponds to a survival fraction of 30-50%.
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Figure 27: Reduction in Incidence compared to Non-Irradiated Control. The reduction in the
incidence of brain metastasis at the eight-week time point is plotted against the radiation dose given on
days 5 and 21, which correspond to experimental irradiation times. The dose was estimated by
extrapolating monolayer clonogenic survival for the MDA-IBC3 cell line and then converting the input
survival fractions in the computational model to dose. While irradiation administered at day 5 results in
an immediate reduction in the incidence of brain metastasis, a slight delay introduces a dose threshold of
approximately 4-6 Gy. This figure shows a striking similarity to findings by Suwinski and Withers [120]
relating to the dose-response of small cell lung cancer to PCI, in which “early” PCI shows an immediate
response (Day 5) while “late” PCI exhibits a dose threshold (Day 21).
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Inclusion of Hypoxia: Effect on Radiation Response
The effect of hypoxia on radiation resistance was included in the model. It was assumed that
the outer 100 microns of the metastasis was fully oxygenated, while the inner, if applicable, was
hypoxic (below). The oxygen enhancement ratio was conservatively estimated as 3.0. As seen
below, the metastases in this model simply were not large enough for hypoxia to be a factor, as
the effect of hypoxia was negligible even when metastases were irradiated late.

Figure 28: Assumptions about Hypoxia in Model. It was assumed that the outer 100 microns of each
metastasis was fully oxygenated, while the core (if applicable) was hypoxic, with an oxygen
enhancement ratio of 3.0. Based on previous work done with our metastatic mouse model, it was
assumed that no necrosis was present. As shown in the bottom panel, the impact of hypoxia was
negligible due to the small size of the metastases.
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SECTION IV. CONCLUSIONS
In Chapter 2, I emphasized that the timing of whole-brain irradiation had a significant impact on
the experimental endpoints of incidence and number of brain metastases and metastatic burden.
Most notably, the sixteen days of additional metastatic growth between 5 and 21 days postinjection produced stark differences in the response to whole-brain irradiation.

Unfortunately,

due to limited experimental groups, no conclusions could be drawn about the time-course of
incidence and other endpoints.

Because of previous clinical meta-analyses suggesting that

“early” PCI is beneficial in the case of SCLC [120], this information gap in our animal
experiment seemed important; in an attempt to bridge that gap, a computational model of
subclinical breast cancer dose-response was developed.
Implementing data from the non-irradiated mice in the PCI experiment, I created a
mathematical model that recapitulates, and expands upon, the experimental results.

Individual

volumes of metastases from the four- and eight-week experimental endpoints were fit to lognormal curves, where the correlation between data and the fits was better than 97% at both time
points.

The log-normal volume fits were then used to generate a range of parameters for the

Gompertz equation. Once the model was built, the input parameters were optimized so that the
correlation between the model and experimental number of metastases per mouse was better
than 95% at both four- and eight-week time points.

The mathematical model was validated

through a limiting dilution assay, where the correlation between model and experimental
incidence was approximately 100%. Because the irradiated mice data was selectively ignored in
the development of the model, it was then possible to use that data for evaluation purposes. By
simulating radiation cell kill, predictions were made regarding how the experimental endpoints
would change as a function of radiation dose and time of irradiation.
The hypothesis was that the computational model of breast cancer brain metastasis doseresponse would underestimate the effect of PCI, and would overestimate the effect of whole94

brain irradiation at three and six weeks post-injection. The comparison of experimental results
with model predictions supported the hypothesis: the computational model predicted that 4-Gy
whole-brain irradiation would decrease the incidence in the PCI group by 30-50% compared to
the non-irradiated control and would decrease the metastatic burden by greater than 40% in the
3- and 6-week treatment groups. In contrast, the experimental reduction in incidence (compared
to the non-irradiated control) was 67-74%; the burden in the treatment groups, while highly
variable, did not demonstrate clear trends away from the control data in either direction. Further
disagreement between the model predictions and experimental results is shown on the next
page.
What the data really suggests is that the survival fraction at 4 Gy – predicted as
approximately 31% from IBC3 clonogenic assays – is not reflected by the experimental results
when comparing against the computational model.

The results from the PCI group in the

experiment are consistent with a 10% survival fraction in the computational model, whereas the
results from the 3- and 6-week treatment groups are highly variable, but more consistent with a
100% than a 31% survival fraction.
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PCI Group, Four-Week Endpoint
Change vs. 0-Gy Control

Model

Experimental

Agreement?

Incidence

-38%

-74%

X

Number of Metastases

-65%

-89%

X

PCI Group, Eight-Week Endpoint
Change vs. 0-Gy Control

Model

Experimental

Agreement?

Incidence

-30%

-67%

X

Number of Metastases

-50%

-93%

X

Metastatic Burden, Upper Quartile
Metastatic Burden, Median

-79%
-91%

-96%
-100%

X

Metastatic Burden, Lower Quartile

-100%

-100%

Three-Week Treatment Group, Four-Week Endpoint
Change vs. 0-Gy Control

Model

Experimental

Agreement?

Incidence

-12%

-9%

Number of Metastases

-37%

-9%

✓
X

Three-Week Treatment Group, Eight-Week Endpoint
Change vs. 0-Gy Control

Model

Experimental

Agreement?

Incidence

0%

+11%

✓

Number of Metastases

-5%

0%

✓

Metastatic Burden, Upper Quartile
Metastatic Burden, Median

-61%
-56%

+340%
-69%

X

Metastatic Burden, Lower Quartile

-63%

-46%

Table X: Comparison between model predictions and experimental results. The experimental
results from the PCI and 3-week treatment groups are compared against the same endpoints from the
computational model, where both the experimental results and model predictions were normalized
against their corresponding non-irradiated control.
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The mechanisms behind this are unknown, but some speculation may be appropriate. In
the case of the whole-brain irradiation at 3 and 6 weeks post-injection, the 4-Gy dose was not
expected (based on the model) to decrease the incidence or the number of metastases per mouse
noticeably, but it was expected to decrease the metastatic burden.

Two well-known factors

involved in radiation response, accelerated repopulation and hypoxia, are worth mentioning.
Hypoxia, which is associated with increased survival due to the lack of oxygen (required for
DNA damage fixation), was aggressively incorporated into the computational model.
the small size of the micrometastases in consideration, it had negligible effect.

Due to

Accelerated

repopulation describes the process by which clonogenic cells attempt to quickly repopulate the
tumor after a large fraction of cells are killed [110].

Although not explicitly included in the

model, accelerated repopulation is a consequence of the assumption that the radiation dose does
not alter the upper limit of tumor growth (i.e. after cell kill, growth rate must increase to reach
same upper growth limit as corresponding non-irradiated lesion).

Even with the inclusion of

these two factors, the difference between observations and predictions remains stark.
Genetic diversity is one factor that may in part explain the difference between the
predictions and results.

As tumors grow, mutations accumulate, and as a consequence

subclones are formed and tumor heterogeneity is observed. This could be significant in terms of
radiation response as one or more of the emergent subclones could exhibit relatively greater
resistance to the effects of radiation therapy. If so, the resistant clone could then repopulate the
tumor [122]. However, in our case the whole-brain irradiation occurs 21 or 42 days after cell
injection, and any genetic diversity would likely be limited.
While the model overestimated the effect of irradiation on the later treatment groups, it
significantly underestimated the effect of irradiation on the PCI group.

Because it is unlikely

that the survival fraction in vivo is less than the survival fraction in vitro at 4 Gy (roughly 30%),
the approximately 10% survival fraction in the PCI experimental group suggests that a non-cell
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kill mechanism is a factor. One possibility is that the radiation precludes the colonization step
in metastasis, as colonization would be expected to occur in first week or two after cell
injection.

For example, one group observed that ionizing radiation induces the epithelial-to-

mesenchymal transition through TGFβ in mammary epithelial cells [123].

Because the

colonization process relies on the opposite of EMT – the mesenchymal-to-epithelial transition
(MET) – one hypothesis would be that ionizing radiation can reverse or block the colonization
process; however, no experimental data supporting this hypothesis exists.

The reduction in the incidence of brain metastasis versus radiation dose curve in Figure
27 mirrors a curve published by Withers and colleagues in a meta-analysis of PCI studies in
small-cell lung cancer patients [120]. In both cases, a delay in the treatment (or the initiation of
treatment) introduces a dose threshold below which no reduction in the incidence of brain
metastasis is observed. In the Withers study, “early” PCI was defined as initiation of treatment
in the sixty days after the completion of a chemotherapy regimen (average start 30 days after
completion), while “late” PCI was defined as initiation of whole-brain irradiation after sixty
days (average 100 days). The dose threshold in that meta-analysis was 20 Gy: there was a linear
relationship between dose and the reduction in incidence, but a delay in treatment shifted the
curve 20 Gy to the right.

That same relationship is observed based on the output of our

computational model, where the 16-day delay between the 5- and 21-day irradiations shifts the
curve approximately 4-6 Gy to the right. In Figure 27, the two curves are not parallel as might
be expected – this is because there is not a log-normal distribution of the number of cells at five
days post-injection: the vast majority of cells have not begun to proliferate. In conclusion, this
computational model of subclinical breast cancer radiation dose response not only recapitulates
the experimental results in the non-irradiation control, but also mirrors the clinical situation for
PCI in SCLC, albeit at lower doses and smaller metastasis volumes.
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As with any computational model, there are clear limitations that result from imperfect
experimental data and the assumptions that form the foundation of the model. In the case of this
model of breast cancer micrometastatic dose response, the assumptions, which are listed in the
methodology section, are major limitations (bias error).

For example, no biological

heterogeneity was included in the model: had it been, the reduction in incidence versus dose
curve would shift to the right. Many of the assumptions followed from the experimental data,
but others were based on the literature and were required to build a usable model.

The

limitations due to the experimental system were discussed in the previous chapter, and will not
be repeated here; however, the experimental results themselves are limitations as they represent
only a small sample of potential outcomes but are the only window we have into the output of
the experimental system.
This last point, differentiation between the experimental system and the experimental
results from our one in vivo study, is very important.

When I was attempting to fit the

experimental number of metastases per mouse and volumes to normal and log-normal curves,
respectively, I am not trying to minimize the error of the fits to the experimental results; rather, I
am trying to minimize the error of the fits to represent the experimental system (generalization
error), which can only be inferred from the experimental results. Attempting to optimize the fits
to the experimental results would be an example of overfitting: the model would be well-tuned
to the results, but may not explain anything about the experimental system.
Combined with the data from Chapter 2, the insights drawn from the computational
model could carry clinical significance, showing that the timing of irradiation is critical for the
treatment of subclinical disease, but that discussion will be withheld until Chapter 6.
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CHAPTER 6: GENERAL DISCUSSION
Breast cancer patients who develop brain metastases have abysmal survival times, with only 1020% surviving beyond one year from the time of diagnosis. Prophylactic cranial irradiation is a
clinical technique used to reduce the incidence of brain metastasis in SCLC and ALL patients
and, because of an emerging population of breast cancer patients at high risk of developing
brain metastasis, there is now interest in extending the technique to select breast cancer patients.
The present work addressed the efficacy of PCI in a mouse model of metastatic, HER2+
inflammatory breast cancer.
The central hypothesis of this thesis was that prophylactic cranial irradiation would
reduce in the incidence of brain metastasis in our mouse model and, in Chapter 2, I described
the results of that in vivo study.

I found that PCI did significantly decrease the incidence of

brain metastasis, the number of metastases per mouse, and the metastatic burden compared to
other experimental groups.

Expanding on those results in Chapter 3 with a computational

model, I mapped the change in the experimental endpoints as a function of survival fraction (i.e.
radiation dose) and time of treatment, demonstrating that not only does the computational model
mimic a clinical situation for SCLC patients, but it also underestimates the effect that PCI had in
the in vivo study.

PCI has been utilized in patients with small-cell lung cancer and acute lymphoblastic
leukemia for forty years, as it reduces the incidence of brain metastasis and consequently
improves overall survival.

Now, with receptor subtypes it is known that HER2+ and triple-

negative breast cancer patients with extracranial metastases have 30% (or greater) risk of
developing brain metastases. Here, I will discuss the potential clinical significance of our data.
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First, it is clear from both the experimental data and the computational model that there
is a significant benefit to earlier treatment. When considering the incidence of brain metastasis
in the model, the timing of irradiation is just as important as the survival fraction. For a given
low survival fraction, there is a period of time where the incidence and the number of metastases
increase rapidly as the treatment is delayed; beyond that critical period, the radiation has little
effect on incidence.
Second, the current clinical scenario is that breast cancer patients will not be referred for
brain scans until they display symptoms consistent with the presence of brain metastases.
Because it is assumed implicitly that all brain metastases are equally bad, it follows that there is
no clinical benefit to earlier treatment, and thus no need to image for the presence of brain
metastases.

This project challenges that assumption, and suggests that there would be a great

clinical benefit to referring patients at high risk of developing brain metastases for brain scans as
part of their follow-up or continued management. But who are these patients? I opened this
discussion in the introduction, but will expand on it below.

If it became the clinical norm that breast cancer patients at high risk of developing brain
metastases did receive MRI scans –before the onset of symptoms – the next step would be to
consider PCI clinical trials for those patients who had negative scans (those with positive scans
would begin WBRT).

The design of clinical trials for these patients would involve several

factors that need to be addressed. Most important, patient selection becomes critical in light of
the potential toxicity of whole-brain irradiation.

I mentioned in the introduction that HER2+

and triple-negative breast cancer patients with extracranial metastases are at the highest risk of
developing brain metastases, and patients outside this subgroup would be unlikely candidates
for PCI.

However, it would be desirable to further segment this subgroup in order to better

define which patients could benefit from PCI.
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The nomogram developed by Ibrahim and colleagues [107] would be a good starting
point. In that study, the authors found the patients at the highest risk were:


Younger



Higher histologic grade



Shorter delay between primary diagnosis and first metastasis



More than one metastatic site

It was estimated that the highest risk patients had 50% probability of developing brain
metastases.

In addition, it could be possible to combine biomarker information with these

clinical factors to better select patients.

For example, high miR-141 in the serum of breast

cancer patients is associated with significantly lower overall survival and progression-free
survival in metastatic breast cancer and inflammatory breast cancer patients [71].

The

combination of omics information and clinical data could define a subset of breast cancer
patients with a greater than 50% risk of developing brain metastases, which is right in line with
the risk of SCLC patients who receive PCI.
One related point that would need to be addressed is whether to restrict PCI to patients
with controlled extracranial disease.

If not, then the patients with uncontrolled extracranial

disease could benefit from early PCI in terms of the incidence of brain metastasis. However,
these patients could very well die from their extracranial metastases, and thus the PCI would
have little effect on overall survival. At the same time, PCI could reduce the burden of brain
metastasis from cells already present in the brain at the time of treatment, but would certainly
not be expected to prevent future re-seeding of the brain by the uncontrolled disease. On the
other hand, if PCI is restricted to patients with controlled extracranial disease, then those
patients with uncontrolled disease may miss their opportunity for early PCI (which could still
benefit them, especially in the case where the disease becomes controlled).
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While patient selection must be considered from the standpoint of which patients are at
the highest risk of developing brain metastasis, the risk of toxicity in individual patients should
be considered as well. For example, there is evidence that neurocognitive decline due to WBRT
or PCI is more pronounced in patients over 75 years of age [111].
Total dose and fractionation schedule would also have to be determined.
patients with extensive disease receive 20-30 Gy in 5-10 fractions [85].

In SCLC,

Patients with brain

metastases often receive 30 Gy whole-brain radiation therapy in ten fractions. It seems likely
that breast cancer patients would receive a similar treatment in terms of dose and fractionation,
but clarifying the lowest effective dose (this could certainly change depending on clinical
factors) could help reduce toxicity. Further, concrete steps could be taken to reduce the risk of
toxicity.

For instance, a recent phase II trial demonstrated that hippocampal avoidance during

whole-brain radiation therapy was associated with memory preservation and improved quality
of life [124], perhaps the two most significant drawbacks of PCI.

In addition, the drug

memantine – often used in patients with memory disorders – was recently evaluated in a large
clinical trial, and the authors found that it delayed the time to cognitive decline and reduced the
rate of decline in memory in patients treated with WBRT [125].

Currently, there is not a consensus on how patients with brain metastases should be
managed.

The current trend is that radiation oncologists are moving away from whole-brain

radiation therapy in favor of stereotactic radiosurgery alone.

A recent report by Saghal and

colleagues [126] found that there was a survival benefit for patients under 50 years of age with
SRS alone. Interestingly, those patients under age 50 who were treated with SRS alone had no
increased risk of developing brain metastases compared to their age-matched cohort in the SRS
+ WBRT arm; however, the risk was significantly greater in patients over age 50 treated with
SRS alone. The authors hypothesize that because there was no significant effect on the distant
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brain failure, the adverse effects of WBRT reduce the survival in patients under 50. This point
stands in contrast to clinical data presented in the nomogram indicating that younger patients are
at higher risk of developing brain metastases [107]. I would note one important difference: the
Saghal study looks at only patients who already have brain metastases.
If the radiation oncology community were to accept that PCI could benefit breast cancer
patients at high risk of developing brain metastases, then it would seem that those breast cancer
patients who already have brain metastases should receive whole-brain radiation therapy, as
they would be high risk (for local/distant brain failure) by definition. The Saghal study seems to
indicate that this may not be the case for younger patients, and emphasizes how much of an
adverse effect that WBRT-associated toxicity can have.

If dose reduction techniques or

hippocampal avoidance are employed, WBRT may gain favor. Last, if whole-brain irradiation
is withheld until disease progression, then the early period where WBRT could show the
greatest benefit might be missed.

I included two chapters in this thesis discussing projects that were early transitions in my
research, but are only tangentially related, if at all, to the principal topic of PCI.

Chapter 4

discusses our findings on how survivin affects radiation response in breast cancer in vitro.
Because survivin is universally overexpressed in cancers and has been shown to be a radiation
resistance factor in many experimental models, there is the possibility that it may promote
survival and recurrence in those clones that survived whole-brain irradiation, especially in the
PCI group. The survivin project fits under the umbrella of attempting to improve the efficacy of
radiation therapy in breast cancer patients, through better understanding of radiobiology and
informing the possible development of radiosensitizers.
The other chapter deals with the hedgehog signaling pathway, and our attempts to
quantify its activity in vivo through the use of radiotracers. The rationale behind this paper and
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related previous studies was that hedgehog signaling could be a surrogate for cancer stem cells,
which are associated with resistance to irradiation. Further, hedgehog activity could potentially
serve as a predictor for treatment response and could help select which patients could benefit
from anti-hedgehog therapies.

While survivin could promote recurrence, quantification of

hedgehog activity before and after irradiation could help predict which patients recur. Because
these studies were transitions, they are far from complete and would need to be expanded upon
in order to address the initial hypotheses.

In this work, I have utilized a unique experimental system – a robust mouse model of
brain metastasis and a small-animal irradiator – in order to address the question of whether PCI
could reduce the incidence of brain metastasis. The overall hypothesis, that PCI would reduce
the incidence of brain metastasis in a mouse model of HER2+ IBC, was supported, and the
computational modeling indicates a divergence between experimental results and model
predictions, and helps to indicate the time period where the experimental endpoints are most
sensitive to changes in radiation dose.

These findings have the potential to inform the debate

surrounding SRS +/- WBRT and the management of breast cancer patients at high risk of
developing brain metastases.
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Survivin is a key member of the inhibitor of apoptosis protein family, and is considered a
promising therapeutic target due to its universal overexpression in cancers. Survivin is implicated in cellular radiation response through its role in apoptosis, cell division, and DNA damage response. In the present study, analysis of publically available data sets showed that
survivin gene expression increased with breast cancer stage (p < 0.00001) and was significantly higher in estrogen receptor-negative cancers as compared to estrogen receptor-positive cancers (p = 9e-46). However, survivin was prognostic in estrogen receptor-positive
tumors (p = 0.03) but not in estrogen receptor-negative tumors (p = 0.28). We assessed the
effect of a survivin dominant-negative mutant on colony-formation (2D) and mammosphereformation (3D) efficiency, and radiation response in the estrogen receptor-positive MCF7
and estrogen receptor-negative SUM149 breast cancer cell lines. The colony-formation efficiency was significantly lower in the dominant-negative survivin-transduced cells versus
control MCF7 cells (0.42 vs. 0.58, p < 0.01), but it was significantly higher in dominant-negative population versus control-transduced SUM149 cells (0.29 vs. 0.20, p < 0.01). A similar, non-significant, trend in mammosphere-formation efficiency was observed. We
compared the radiosensitivity of cells stably expressing dominant-negative survivin with
their controls in both cell lines under 2D and 3D culture conditions following exposure to increasing doses of radiation. We found that the dominant-negative populations were radioprotective in MCF7 cells but radiosensitive in SUM149 cells compared to the controltransduced population; further, Taxol was synergistic with the survivin mutant in SUM149
but not MCF7. Our data suggests that survivin modulation influences radiation response differently in estrogen receptor-positive and estrogen receptor-negative breast cancer subtypes, warranting further investigation.
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Introduction
Survivin is the smallest member of the inhibitor of apoptosis protein (IAP) family at 16.5 kDa
and is encoded by BIRC5 (baculoviral inhibitor of apoptosis repeat-containing protein-5) [1]. It is
implicated in the regulation of several cellular networks, and is prominent for its universal overexpression in human cancers. Survivin harbors many phosphorylation sites and interacts with a
variety of different proteins, enabling its diverse functions that include its involvement in cellular
division, apoptosis, intracellular signaling, and adaptation to unfavorable environments [2].
Survivin is clinically relevant in breast cancer and may be predictive of response to therapy.
One of the seminal studies found that survivin is expressed in approximately 70% of breast carcinomas compared to no expression in adjacent normal tissue, and that survivin expression is a significant prognostic parameter of worse outcome in breast cancer patients [3]. Further, Kennedy
and colleagues [4] found that nuclear survivin expression is prognostic of favorable outcome for
breast cancer patients. A more recent study reported that survivin expression could function as a
predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients
with stage II or stage III breast cancer [5]. Interestingly, survivin is a component of the 21-gene
recurrence score validated in ER+ node-negative patients as a prognostic and predictive marker
of recurrence and response to chemotherapy [6]. More recently, retrospective analysis of clinical
trials from which these studies were validated revealed the recurrence score also predicts for risk
of local recurrence among patients treated with lumpectomy and radiation [7].
Survivin, due in part to its role in apoptosis, and cell division, has long been proposed as a
predictive factor for response to radiation therapy treatments, and anti-survivin treatments
have been explored as possible radiosensitizers in preclinical studies [8]. More recently, it has
been reported that survivin also plays a role in DNA double-strand break repair [9], adding another mechanism by which survivin may increase cellular radio-resistance. Several preclinical
studies have shown that survivin is associated with radiation resistance in pancreatic cancer
[10], colorectal cancer [11], melanoma [12], lung cancer [13], glioblastoma [14], and epidermoid carcinoma [15]. Further, several of these and other preclinical studies [16] [17] [18] [19]
tested the efficacy of anti-survivin treatments—including the use of antisense oligonucleotides,
siRNA, ribozymes, dominant-negative mutants, and small-molecule inhibitors—in combination with radiation. In each case, the combination treatment was more effective than radiation
alone, and increased apoptosis as well as decreased cell survival and growth were observed in
the combined regimen. In murine mammary epithelial cells, Woodward and colleagues [20]
[21] reported that survivin is selectively upregulated following irradiation in stem cell-enriched
populations; however, no group has specifically examined if survivin is a radiation resistance
factor in breast cancer cells.
In the present study, we examined public gene expression datasets and report that although
survivin expression is higher in estrogen receptor-negative (ER−) than estrogen-receptor-positive
(ER+) breast cancer, it is only prognostic in ER+ breast cancer. Based on the differential impact
that survivin expression has on overall survival in ER+ and ER− breast cancer patients, we hypothesized that survivin perturbation would exert different effects on an ER+ versus an ER− cell
line. We evaluated how a phosphorylation-defective mutant of survivin (survivin-DN) affects apoptosis, self-renewal capacity, and radiation response in ER+ and ER− breast cancer cell lines.

Materials and Methods
Data Mining
BIRC5 expression in different breast cancer patient cohorts was extracted from two public databases, Oncomine [22] and Gene Expression-Based Outcome for Breast Cancer Online
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(GOBO) [23]. In Oncomine, data was specifically extracted from The Cancer Genome Atlas,
Bittner (unpublished), and Curtis [24] breast datasets. BIRC5 expression was then stratified
based on three characteristics: presence of invasive carcinoma, stage, and receptor status.
Breast cancer patient survival information (all breast cancer patients, ER+ patients, or ER−
patients) was evaluated in the Kaplan-Meier Plotter (K-M Plot) [25] and GOBO public databases, where patients were stratified into groups of high and low BIRC5 expression using a database-selected “cutoff” point.

Cell culture
The estrogen receptor-positive breast cancer cell line MCF7 was acquired from ATCC and cultured in Modified Eagle Medium (MEM) supplemented with 10% fetal bovine serum, 0.1 mM
nonessential amino acids, 1 mM sodium pyruvate, 1 μg/mL hydrocortisone, 5 μg/mL insulin,
and 1% antibiotic-antimycotic. The triple-negative, inflammatory breast cancer cell line
SUM149 was obtained from Asterand (Detroit, MI, USA) and was cultured in Ham’s F-12
media supplemented with 10% fetal bovine serum (FBS), 1 μg/mL hydrocortisone, 5 μg/mL insulin, and 1% antibiotic-antimycotic. Cell lines were maintained at 37°C in a humidified atmosphere (5% carbon dioxide).

Construct
In order to generate a survivin dominant-negative mutant, an adenoviral construct with a survivin-T34A point mutation, kindly provided by Dr. Altieri and colleagues [26], was acquired.
The green fluorescent protein from the pFUGW backbone [27] was removed, after which the
survivin dominant-negative construct (survivin-DN) was cloned into the HindIII-BamHI site.
pFUGW was used as a negative control throughout the study.

Western blot
Western blots were run to validate induction of the survivin-DN construct and to evaluate caspase cleavage as a marker for apoptosis in both MCF7 and SUM149 cell lines. The lysate was
collected with 1X RIPA lysis buffer (diluted from 10X RIPA from Cell Signaling, Danvers, MA)
containing 1 uM phenylmethyl sulfonyl fluoride and was transferred to microcentrifuge tubes.
The samples were rotated for one hour at 4°C and centrifuged at 10,000 g for 10 minutes.
Fifty-μg aliquots of the protein lysate supernatants were electrophoresed on 4–20% gradient
sodium dodecyl sulfate-polyacyrlamide gels (Invitrogen, Life Technologies, Carlsbad, CA) and
transferred to polyvinylidene fluoride membranes (Bio-Rad Laboratories, Hercules, CA). The
membranes were incubated in 5% non-fat milk for one hour at room temperature and then
incubated at 4°C for 16 hours with the primary antibody: rabbit anti-survivin mAb (Cell Signaling #2808, Danvers, MA), rabbit anti-caspase 3 mAb (Cell Signaling #9662) and rabbit anticleaved capsase 3 mAb (Cell Signaling #9664). The membranes were then washed three times
and incubated with the corresponding secondary antibody conjugated with horseradish peroxidase (Santa Cruz, CA) in 5% non-fat milk at room temperature. Next, the membranes were
washed three times and immunoreactivity was detected by enhanced chemiluminescence. For
all western blots, mouse anti-β-actin mAb (Sigma-Aldrich #A5316, St. Louis, MO) was used as
a loading control.

Cell cycle assay
Cell cycle analyses were performed as described previously [28]. Briefly, cells were enzymatically dissociated and centrifuged for 5 minutes at 4°C. After washing once with PBS, cells were
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fixed with 70% cold ethanol and were left overnight at 4°C. Cells were then centrifuged and resuspended in a Propidium Iodide solution (50 μg/mL Propidium Iodide). RNase (20 μg/mL)
was added and samples incubated at 37°C for 1 hour. Samples were then immediately analyzed
for DNA content using FACSAria II flow cytometer from Becton-Dickinson (BD Biosciences,
San Jose, CA), and the distribution of cells across cell phases was analyzed using FlowJo software (Treestar, Ashland, OR).

Mammosphere cultures
Cancer stem/progenitor cells can be enriched by propagating cells in serum-free, growth factor-enriched conditions—called mammospheres (3D) cultures in the case of breast cancer [29].
To generate mammospheres from MCF7 and SUM149 cells, 2 x 104 cells/mL were cultured in
serum-free MEM supplemented with 20 ng/mL basic fibroblast growth factor (Invitrogen),
20 ng/mL epidermal growth factor (Invitrogen), and B27 (Invitrogen) in six-well, ultra-low
attachment plates.

Clonogenic assays
The radiosensitivity of the survivin-DN construct in both monolayer (2D) and mammosphere
(3D) cultures was evaluated as described previously [30]. For both 2D and 3D radiosensitivity
assays, single cells from dissociated MCF7 and SUM149 monolayer cultures were seeded into
6-well tissue culture plates. The 6-well plates containing seeded cells were irradiated with γ-irradiation (0, 2, 4, or 6 Gy) four hours after plating with a 137Cs source (Shepherd Irradiator, J.
L. Shepherd and Associates, San Fernando, CA). For 2D monolayer culture, the plates were incubated for 14 days, after which the colonies were stained with crystal violet and then counted
manually. For 3D mammosphere cultures, the cells were incubated in mammosphere media
for 7 days, and then the spheres were stained with MTT to improve visualization.
In a separate set of experiments, mammosphere cultures were incubated with either 10 nM
Taxol (Cayman Chemical, Ann Arbor, MI) or 1 μM GSI (CalBiochem, Darmstadt, Germany).
Spheres with a minimal size of 50 μm were counted using a GelCount colony counter (Oxford
Optronix, Oxford, UK). Linear-quadratic survival curves were generated using SigmaPlot, version 8.0 (Systat Software, San Jose, CA).

Tissue Staining
Primary MCF7 and SUM149 tumor xenograft tissue was used for immunohistochemical staining to detect survivin and phospho (pT34)-survivin with the rabbit anti-survivin mAb (Cell
Signaling #2808, Danvers, MA) and rabbit anti-pT34-survivin (Santa Cruz, sc-23758)
antibodies, respectively.

Statistical Analysis
Statistical analyses were performed in GraphPad Prism version 6. Two-tailed Student’s t test
was used to evaluate colony- and mammosphere-formation efficiency and to compare group
means in the clonogenic assay, with p < 0.05 considered statistically significant.

Results
We investigated the relevance of survivin to breast cancer by extracting BIRC5 expression information from three public databases: Oncomine [22], Gene Expression-Based Outcome for Breast
Cancer Online (GOBO) [23], and Kaplan-Meier Plotter (K-M Plot) [25]. We found that BIRC5
was expressed significantly higher in invasive breast carcinoma compared to normal breast
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Fig 1. Survivin expression in breast cancer from public databases. A) Survivin expression is approximately seven-fold higher in invasive breast
carcinoma compared to normal breast (p = 5.5e-31) from the TCGA data set in the Oncomine public database. B) From the GOBO public dataset, survivin
expression increases with breast cancer stage (p < 0.00001). C) Survivin is expressed 2.3-fold higher in triple-negative breast cancer compared to all other
molecular subtypes (p = 3.5e-8) in the Bittner breast data set in Oncomine. D) Similarly, survivin expression is 2.3-fold higher in estrogen receptor-negative
compared to estrogen receptor-positive breast cancers (p = 9e-46) in the Curtis breast data set [24] in Oncomine.
doi:10.1371/journal.pone.0120719.g001

tissues (Fig. 1A, p = 5.5e-31) and increased with breast cancer stage (Fig. 1B, p < 0.00001).
Moreover, BIRC5 was expressed significantly higher in triple-negative breast cancer, a type of
breast cancer known to be more aggressive and with poor prognosis, compared to all other
combined subtypes (Fig. 1C, p = 3.5e-8). Furthermore, BIRC5 was expressed over two-fold higher
in estrogen receptor-negative (ER−) breast cancers compared to estrogen receptor-positive
(ER+) breast cancers (Fig. 1D, p = 9e-46).
To determine whether survivin expression correlates with prognosis in patients with ER+
and ER− tumors, we analyzed two public breast cancer databases which had outcome data [22]
[25]. In K-M Plot, we found that high BIRC5 expression is associated with poor overall survival
in all breast cancers patients (Fig. 2A, p = 0.0002) and in patients with ER+ breast cancer
(Fig. 2C, p = 0.03), but was not associated with response in ER− patients (Fig. 2E, p = 0.28).
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Fig 2. Overall survival in breast cancer stratified by survivin expression using two public databases.
Kaplan-Meier Plotter (A,C,E) and Gene Expression-Based Outcome for Breast Cancer Online (B,D,F) data
are shown. Red = high survivin expression at selected cutoff expression. A,B) High survivin expression is
prognostic for poor outcome in all breast cancer patients. C,D) Likewise, high survivin expression predicts for
poor outcome in patients with estrogen receptor-positive breast cancer. E,F) In patients with estrogen
receptor-negative breast cancer, survivin expression is not associated with clinical outcome.
doi:10.1371/journal.pone.0120719.g002

Similar results were observed in the second database with respect to overall survival in all breast
cancer patients, ER+ patients, and ER− patients (Fig. 2B, D, F).
To functionally assess whether survivin plays a significant role in the radiation response of
breast cancer, we generated a survivin dominant-negative construct by cloning a T34A mutant
into a pFUGW lentiviral backbone. As has been observed in T34A-transfected 293T cells by
Altieri’s group [26], we found induction of the dominant-negative mutant in MCF7 and SUM149
cell lines (Fig. 3A). Normally, this threonine residue would be phosphorylated by p34(cdc2)-cyclin B1, which is important in survivin protein stability and trafficking [31]. We first assessed the
effect of the dominant-negative mutant on the frequency of apoptosis in MCF7 and SUM149 cell
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Fig 3. Cells transduced with the survivin dominant-negative construct display higher levels of
apoptotic markers. A) MCF7 and SUM149 breast cancer cell lines were successfully transduced with the
survivin dominant-negative construct, as shown by Western blot. B) Survivin-DN cells display greater levels
of cleaved caspase 3 compared to the control; MCF7 shows no expression of caspase 3, consistent with the
literature [32]. C) Survivin-DN cells have a greater fraction of sub-G1 (i.e. apoptotic) cells compared to the
control, when stained with Propidium iodide.
doi:10.1371/journal.pone.0120719.g003

lines with caspase cleavage and cell cycle assays. In the caspase cleavage assay, the survivin-DNtransduced SUM149 cells showed greater levels of caspase cleavage compared to the pFUGW
control (Fig. 3B). MCF7 did not express caspase 3, consistent with the literature [32].
In cell cycle assays we stained both cell lines with Propidium Iodide, and measured the
number of cells in the sub-G1 phase of the cell cycle as a surrogate for apoptosis. In the
SUM149 survivin-DN population, 7.2% of cells were in the sub-G1 phase, compared to only
3.4% of cells in the control population (Fig. 3C). Similarly, there was also a higher percentage
of cells in sub-G1 phase for the survivin-DN population compared to the control in MCF7 cells
(Fig. 3D).
We then evaluated the effect of the T34A survivin mutation on colony- and mammosphereformation assays. In the ER+ MCF7 cell line, colony-formation efficiency was significantly lower
in the survivin-DN population as compared to the control (Fig. 4A, 0.42 vs. 0.58, p < 0.01). In
the ER− SUM149 cell line, however, the survivin-DN cells had significantly greater colonyformation efficiency (Fig. 4B, 0.29 vs. 0.20, p < 0.01). No significant difference in mammosphereformation efficiency was observed between survivin-DN and control in either cell line (Fig. 4C,
4D, p > 0.05).
Next, we sought to investigate how the survivin-DN construct affects radiation sensitivity in
MCF7 and SUM149. For both cell lines, clonogenic assays were performed with single-dose irradiation in monolayer and mammosphere conditions, and with fractionated radiation under
mammosphere conditions. In all three conditions in MCF7, survivin-DN was radio-protective,
with the survivin-DN-transduced MCF7 cells showing more resistance to irradiation than
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Fig 4. Colony- and mammosphere-formation efficiency in MCF7 and SUM149 breast cancer cell lines. A) In MCF7, the FUGW control forms
significantly more colonies than the survivin-DN-transfected cells (p < 0.01). B) In SUM149, the survivin-DN cells form significantly more colonies than the
control (p < 0.01). C,D) In both MCF7 and SUM149, there is no statistical difference in mammosphere-formation efficiency between the control and survivinDN clone. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0120719.g004

control-transduced MCF7 cells (Fig. 5A, C, E). In the SUM149 monolayer cultures, however,
survivin-DN-transduced cells were radiosensitized compared to the control-transduced cells
(Fig. 5B, 5D). Radiation response between different groups can also be compared by calculating
surviving fraction at 2 Gy (SF2) values. For MCF7, survivin-DN was slightly radioprotective
under all plating conditions, while survivin-DN was slightly radiosensitized compared to the
control in SUM149 (Table 1).
We investigated the synergy of survivin perturbation and chemotherapy by adding Taxol to
both the control and survivin-DN populations in MCF7 and SUM149 cell lines. In Taxol-treated cells, there were no significant differences between control and survivin-DN MCF7 cells
(Fig. 6A, p > 0.05). In SUM149 cells, however, the combined regimen with Taxol and survivinDN significantly decreased mammosphere-formation efficiency compared with survivin-DN
alone (Fig. 6B, 0.002 vs. 0.004, p < 0.001). We also evaluated the synergy of a gamma secretase
inhibitor with survivin-DN in both cell lines, but no significant differences were observed
(Fig. 6C, 6D, p > 0.05).
After staining SUM149 and MCF7 tissues for pT34-survivin in order to quantify the background activity of survivin, no differences were observed (S1 Fig.). Further, the total survivin
and phospho-survivin was localized in the nucleus in both the control and survivin-DN
SUM149 clones (S2 Fig.).
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Fig 5. Representative figures for monolayer and mammosphere clonogenic assays in MCF7 and SUM149. A,C,E) MCF7 survivin-DN cells are radioprotective in monolayer cultures, mammosphere cultures, and also mammosphere cultures undergoing a fractionated regimen. B) SUM149 survivin-DN cells
are radiosensitive compared to the control in monolayer cultures. D,F) SUM149 survivin-DN cells show no statistical difference in response to radiation, for
both mammosphere cultures and mammosphere cultures exposed to a fractionated regiment. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0120719.g005

Discussion
Here we report that T34A, phosphorylation-defective survivin reduces colony and mammosphere formation in the ER+ MCF7 cell line but not in the ER− SUM149 cell line. Conversely,
the phosphorylation-defective survivin synergizes with taxol and radiation in an ER− cell line,
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Table 1. Survival Fraction at 2 Gy for survivin-DN in MCF7 and SUM149.
Control

Survivin-DN

MCF7 2D

0.23 (13)

0.30 (16)

MCF7 3D

0.60 (23)

0.63 (19)

SUM149 2D

0.17 (08)

0.15 (12)

SUM149 3D

0.89 (19)

0.82 (20)

doi:10.1371/journal.pone.0120719.t001

SUM149, but not in the ER+ MCF7, suggesting that the primary function of survivin in these
cell lines and potentially in ER+ and ER− tumors is different.
We extracted information from three public databases regarding expression of BICR5, the
gene that encodes survivin. We found that increased BIRC5 expression is associated with advanced stage and ER− disease, but is prognostic only in ER+ breast cancer patients. These data
raise important questions about targeting survivin in ER+ and ER− tumors and lead to the
speculation that the dominant function of survivin in ER+ tumors may be promotion of progression, while in ER− tumors it may be regulation of response. This is consistent with the
well-documented clinical paradox of greater response but worse overall outcomes in patients
with ER− breast cancer who receive neoadjuvant chemotherapy.
Evasion from apoptotic death is a key mechanism in the response to therapy, in effect resistance of cancer cells to ionizing radiation and chemotherapy. Indeed, it is considered a

Fig 6. Mammosphere-formation efficiency in MCF7 and SUM149 when selected drugs are administered to survivin-DN cells. A,C) Neither Taxol nor
gamma secretase inhibitor decrease mammosphere-formation efficiency in MCF7 control or survivin-DN cells. B) SUM149 survivin-DN cells are sensitized
by treatment with 10 nM Taxol (p < 0.001). D) Gamma secretase inhibitor shows no effect on mammosphere formation in SUM149 control or survivin-DN
cells. Error bars indicate standard deviation.
doi:10.1371/journal.pone.0120719.g006
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hallmark of cancer. Changes in the activity of apoptotic pathways thus influence the response
to anti-cancer treatments, and disruption of these pathways by interfering with anti-apoptotic
factors is an attractive strategy to counteract therapeutic resistance. Survivin, an inhibitor of
apoptosis protein that is universally overexpressed in human cancers, represents one
such target.
To assess the relevance of survivin function to colony formation and radiation response in
breast cancer, we employed the T34A phosphorylation-defective survivin in ER+ MCF7 and
ER− SUM149 breast cancer cell lines, performing apoptosis, colony- and mammosphere-formation, and clonogenic assays. As we have reported before [30], the colony-formation and clonogenic assays performed under monolayer conditions may not fully reflect the effect of
treatment on the stem and progenitor cell fraction, which is often enriched after treatment.
The mammosphere assay, however, is thought to select for the self-renewing, stem cell fraction,
and because of the greater relative resistance of stem cells compared to more differentiated cells
to conventional treatments, we observed greater sensitivity of the monolayer cultures to irradiation compared to the mammosphere cultures as we and others have published previously
[33,34,35]. Interestingly, there were greater differences in radiosensitivity between the control
and phosphorylation-defective survivin populations in monolayer cultures as compared to
mammosphere cultures; however, this may be due to the extreme radioresistance of the 3D cultured cells. Finally, we explored the combination of the survivin dominant-negative mutant
with either Taxol or a gamma secretase inhibitor, as Notch signaling has been reported to increase survivin levels in basal-like breast cancer but not in ER+ breast cancer [36,37]. Absolute
differences were detected only in the ER+ cells; however, these were modest and
not significant.
Numerous attempts to target survivin in preclinical breast cancer models have been successful. One group employed the T34A phosphorylation-defective survivin to mitigate the growth
and metastatic potential of a 4T1 mouse model of breast cancer [38]. In a separate study, the
administration of a small-molecule survivin suppressant led to a regression of the primary and
reduced spontaneous metastases in the triple-negative mouse model of breast cancer [39]. The
results from these studies do not parallel our findings in the databases, in which survivin was
not prognostic in estrogen receptor-negative breast cancer; further, we found that the phosphorylation-defective survivin increased colony-formation efficiency in the triple-negative
SUM149. Nevertheless, all results consistently highlight the potential clinical benefit to abrogating survivin function in breast cancers.
A relationship between survivin and estrogen has been reported previously. Frasor et al.
[40] observed that estradiol upregulates survivin expression in the ER+ MCF7. A mechanism
was established by Sayeed and colleagues [41], who found in chromatin immunoprecipitation
assays that estrogen upregulates survivin through a p53-dependent mechanism. ERα interacts
with p53 bound to the promoter of survivin, inhibiting p53-mediated transcriptional repression of survivin and opposing p53-mediated apoptosis in breast cancer cells. Span et al. [42]
suggested that higher survivin expression in ER− cells may be due to a difference in the cellular
origin of ER− (as compared to ER+) tumors rather than due to differences in estrogen-mediated survivin expression. Chen et al. [43] observed that, among twenty endometrial hyperplasia
patients that responded to progestin therapy, there was a twenty-fold decrease of nuclear survivin expression and eight-fold decrease in cytoplasmic survivin expression; conversely, there
was no change in survivin expression among non-responders. These data implied that high
survivin in ER+ cells is a function of unopposed estrogen in ER+ tumors, and that treatmentresponsive tumors reduce survivin expression.
In conclusion, we describe the disparate effect of a dominant-negative form of survivin on
the colony-forming potential and radiation response in ER+ and ER− breast cancer cell lines.
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This study provides insight into the interaction between estrogen and survivin and highlights
further study is warranted regarding survivin targeting to enhance therapy in ER− disease versus reduce progression in ER+ disease.

Supporting Information
S1 Fig. Survivin activity in MCF7 and SUM149 xenograft tissue.
(TIF)
S2 Fig. Staining of SUM149 primary tumor xenograft for survivin.
(TIF)
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High tumor hedgehog expression is correlated with poor prognosis in invasive ductal carcinoma. Peptides which bind the patched
receptor have recently been reported to have a growth inhibitory effect in tumors with activated hedgehog signaling. We sought
to examine growth inhibition with these peptides in breast cancer cells and use these peptides as molecular imaging probes to
follow changes in hedgehog expression after chemotherapy. Significant growth inhibition was observed in breast cancer cell lines
treated with PTCH-blocking peptides. Significant in vitro uptake was observed with both FITC- and 99m Tc-EC-peptide conjugates.
In vivo imaging studies displayed greater accumulation of 99m Tc-labeled peptides within tumors as compared to adjacent muscle
tissue. Patched receptor expression increased after treatment and this correlated with an increase in tumor radiotracer uptake. These
studies suggest that peptides which bind the sonic hedgehog docking site in patched receptor correlate with patched expression and
can be used to image patched in vivo. Further, our data suggest that radiolabeled peptides may enable us to examine the activity of
the hedgehog signaling pathway and to evaluate response to anti-cancer therapies.

1. Introduction
The hedgehog (Hh) signaling pathway plays a critical role in
embryonic development and wound healing, and its aberrant
activity is associated with several malignancies. Recent studies implicate Hh signaling in breast cancer growth and metastasis, and high tumor sonic hedgehog (SHh) expression is
correlated with poor prognosis in invasive ductal carcinoma.
SHh binds to the suppressive receptor patched-1 (PTCH1) and relieves the inhibition of the transmembrane protein
smoothened (Smo) by PTCH-1, resulting in the translocation
of Gli transcription factors to the nucleus and activation of
Hh target genes. In tumors with activated Hh signaling, high
levels of PTCH-1 have been reported, especially within the
tumor stroma.
Previously, we demonstrated strong detection of tumor
xenografts using an iodinated derivative of the PTCH-1

binding ligand, sonic hedgehog [1]. Although this agent was
capable of delineating tumor tissue, its clinical utility is
limited due to poor stability and pharmacokinetics. Imaging
with radiolabeled peptides has been shown to improve
pharmacokinetics and the targeting of other tumor-based
receptors. Therefore, we sought to develop radiolabeled peptides which dock inside the PTCH receptor. Nakamura et al.
previously reported the synthesis of several peptides targeting
the PTCH-1 receptor [2]. These peptides were shown to bind
to the PTCH-1 receptor on the surface of pancreatic tumors
and decrease tumor growth.
Here, we selected technetium-99 m (99m Tc) as the radioisotope because of its favorable physical characteristics for
diagnostic imaging studies and due to the ease of using its
benchtop generator-based system for clinical applications. It
emits 140 keV gamma ray, with an 89% branching fraction,

2
which can be detected by single photon emission computed
tomography (SPECT). In addition, the half-life of 99m Tc
is relatively long (6.02 h) compared to most nuclear imaging radioisotopes, which facilitates serial imaging that may
improve the differentiation of tumor from inflammation. To
label the peptide with 99m Tc, the chelator N,N -ethylenedi-L-cysteine (EC) is selected and used as a linker. EC is
known to chelate 99m Tc stably owing to the efficient binding
of the oxotechnetium group to the two thiols and two amine
nitrogen atoms of EC.
Here, we report the radiolabeling of these peptides to
detect the PTCH receptor on breast cancer cells and breast
cancer stem cell-enriched populations. These molecular
imaging probes have the potential to identify Hh-induced
changes in PTCH-1 expression, which is useful for the
imaging of aberrant Hh signaling in malignancies.

2. Methods
2.1. Peptides. PTCH-binding peptides A—sequence FAPVLDGAVSTLLGV— and B—sequence DNTRYSPPPPYSSHS—
were commercially synthesized with or without an N-terminal FITC-Ahx modification (GenScript, Piscataway, NJ).
Peptides were resuspended at a stock concentration of
200 𝜇M in 10% DMSO in deionized water.
2.2. Synthesis and Radiolabeling of PTCH. Ethylenedicysteine
(EC) was selected as a chelator for PTCH conjugation.
Sodium bicarbonate (1 N, 1 mL) was added to a stirred
solution of EC (5 mg, 0.019 mmol). To this colorless solution,
sulfo-NHS (4 mg, 0.019 mmol) and EC (5 mg, 0.019 mmol)
were added. PTCH (0.3 mg) was then added. The mixture
was stirred at room temperature for 24 hours. The mixture
was dialyzed for 48 hours with a cutoff at molecular weight
10,000 Da. After dialysis, the product was freeze-dried, with
the product in the salt form weighing 0.5 mg.
99m
Tc-pertechnetate was obtained from Mallinckrodt
(Houston, TX). Radiosynthesis of 99m Tc-EC-PTCH was
achieved by adding the required amount of 99m Tcpertechnetate into EC-PTCH (0.1 mg) and tin chloride
(II) (SnCl2 , 100 mg). The mixture was loaded on a sephadex
gel column (PD-10, G-25) (Sigma Chemical Company, St.
Louis, MO) and eluted with phosphate-buffered saline (pH
7.4). One milliliter of each fraction was collected. The product
was collected at fraction 3, with a 70% yield. Radiochemical
purity was assessed by Radio-TLC (BioScan, Washington,
DC) using saline as an eluant.
2.3. Cell Lines and Culture Conditions. The human cell lines
T47-D, SKBR3, and MCF-7 were obtained from the American
Type Tissue Company (ATCC) and cultured in DMEM
with 10% fetal bovine serum (Atlanta Biologicals, Flowery
Branch, GA) and 1% antibiotic-antimycotic (Invitrogen Life
Technologies, Grand Island, NY Life Technologies, Grand
Island, NY). The human cell line SUM159 was obtained from
Asterand (Detroit, MI) and cultured in DMEM containing 1 𝜇g/mL hydrocortisone (Invitrogen Life Technologies,
Grand Island, NY Life Technologies, Grand Island, NY),
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5 𝜇g/mL insulin (Invitrogen Life Technologies, Grand Island,
NY), and 1% antibiotic/antimycotic. The rat breast cancer cell
line 13762 was derived from a tumor induced in a Fischer-344
rat by giving an oral dose of 7,12-dimethylbenz[a]anthracene
[3], and the cells were cultured in RPMI-1640 medium,
supplemented with 10% (vol : vol) fetal bovine serum and
1% antibiotic-antimycotic. For mammosphere assays, cells
were cultured in MEM media supplemented with 1X B27
(Invitrogen Life Technologies, Grand Island, NY), 20 ng/mL
epidermal growth factor (EGF; Invitrogen Life Technologies,
Grand Island, NY), and 20 ng/mL basic fibroblast growth
factor (bFGF; Invitrogen Life Technologies, Grand Island,
NY) and seeded into ultralow attachment plates (Corning
Life Sciences, Salt Lake City, UT). Cells were grown for 7–
10 days and spheres were obtained. All cells were cultured
at 37∘ C in a humidified atmosphere containing 5% carbon
dioxide.
2.4. Survival Assays. Breast cancer cell lines were seeded
into 96-well plates at a density of 5,000–7,000 cells per
well. Cells were grown overnight and media were replaced
with culture media containing unlabeled peptides A and
B at the indicated concentrations. Cells were cultured for
an additional 48 hours and survival was determined using
the MTT-based Cell Proliferation Assay (Biotium). Data is
expressed as %treated/untreated.
2.5. Fluorescence Microscopy. Breast cancer cell lines were
seeded onto chamber slides (Nunc, Roskilde, Denmark) and
grown overnight. For sphere assays, cells were seeded in 3D
media as described above in 96-well low attachment plates
at a density of 100–1000 cells per well and cultured for 7–
10 days until spheres were formed. Spheres were filtered
using a cell strainer and replated into low attachment plates.
Cells or spheres were treated with 100 nM peptide A or B
and incubated for 2 hours. Media were removed and cells
or spheres were washed two times with 1X PBS. Following
washes, 1 mL of 1X PBS was added to the slide or plate and
cells or spheres were analyzed by fluorescence microscopy
using a Zeiss motorized AxioObserver Z1 microscope. For
co-localization experiments, cells were seeded at a density of
7000 cells per well in a chamber slide and cultured overnight.
Cells were incubated with 100nM peptide and incubated for
2 hours. Cells were fixed in methanol at -20 degrees Celsius
for 5 min, and blocked with PBS containing 10% goat serum.
Cells were stained with anti-PTCH antibody (Santa Cruz
Biotechnology, Dallas, TX) overnight at 4 degrees Celsius,
washed 3 time in 1XPBS and incubated with an anti-rabbit
Alexa-555 secondary antibody for 1 hour at RT. Slides were
washed 3 times with PBS and stained with DAPI Prolong
Gold (Invitrogen Life Technologies, Grand Island, NY). Slides
were analyzed using a Zeiss motorized AxioObserver Z1
microscope.
2.6. Uptake Studies. To measure uptake of the FITC-tagged
peptide, cells were plated at a density of 5,000–10,000 cells
per well in a 24-well plate and grown overnight. For sphere
assays, cells were plated as described above. Cells or spheres
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Figure 1: Patched-binding peptides decrease growth of the SKBR3 breast cancer cell line. Using the MTT assay, peptides A and B administered
to SKBR3 significantly decreased growth compared to untreated cells. Error bars represent standard deviation. Significance is represented by
asterisk. ∗ 𝑃 ≤ 0.05.

were treated with 100 nM peptide and incubated for 2 hours.
Cells or spheres were washed 3X with PBS, trypsinized, and
resuspended in 500 𝜇L culture media. Cells were counted
using a Countess automated cell counter (Invitrogen Life
Technologies, Grand Island, NY Life Technologies, Grand
Island, NY) after staining with trypan blue (Invitrogen Life
Technologies, Grand Island, NY Life Technologies, Grand
Island, NY). Next, 100 𝜇L of cell suspension was transferred to
black polystyrene 96-well plates. Fluorescence was measured
at 485 nm excitation and 535 nm emission. Uptake is reported
as mean fluorescence intensity per 1,000 cells.
The rat breast carcinoma cell line 13762 and the human
breast cancer cell lines SUM159 and MDA-IBC3 were used
for the in vitro radiotracer uptake. One day before the uptake
experiment, 2 × 105 cells/well of each cell line were seeded
in six-well plates and incubated at 37∘ C in 5% CO2 under
humidified conditions. The following day, 300 kBq of 99m TcEC-peptide A or 99m Tc-EC was added with 2 mL of the appropriate media to each of the wells. The cells were incubated for
30 minutes, 1 hour, 2 hours, or 4 hours, after which the media
was aspirated, cells were washed twice with PBS, and then
cells were suspended with trypsin. Radioactivity of collected
cells was measured on a gamma counter (Packard) with an
energy window of 126–154 keV for 99m Tc, and percent uptake
was calculated by using an appropriate standard. Percent
uptake was then normalized to milligrams of protein in the
sample, where the protein concentration was measured using
the Bradford method (Bio-Rad Laboratories, Berkeley, CA).
Each sample was run in triplicate, with error bars indicating
standard deviation.

breast carcinoma cell suspension (105 cells/rat of a breast
tumor cell line specific to Fischer rats) into the hind legs
using 25-gauge needles. Studies were performed 12–14 days
after inoculation when tumors reached approximately 1 cm
in diameter. For treatment studies, rats were injected with
20 mg/kg paclitaxel and reimaged 7 days later. After the
posttreatment scan, tumors were removed and formalin sections were made. Control tumors were taken from untreated
mice 13 days after inoculation. Sections were stained with an
anti-patched antibody (Santa Cruz) using a peroxide-based
immunohistochemical detection kit (Dako) according to the
manufacturer’s instructions.

2.7. Animal Model and Chemotherapy Treatment. All animal
work was carried out in the Small Animal Imaging Facility
(SAIF) at the University of Texas M.D. Anderson Cancer
Center under an approved Institutional Animal Care and
Use Committee (IACUC) protocol. Female Fischer 344 rats
(150 ± 25 g, 𝑛 = 6) (Harlan Sprague-Dawley, Indianapolis,
IN) were inoculated subcutaneously with 0.1 mL of a 13762

3. Results

2.8. Planar Imaging. Planar scintigraphic images were
obtained using M-CAM (Siemens Medical Solutions, Hoffman Estates, IL) equipped with a low energy high resolution
(LEHR) collimator. Anesthetized breast tumor-bearing
rats were injected intravenously with 99m Tc-EC-peptide
A (0.3 mg/rat, 300 𝜇Ci/rat; 𝑛 = 3) before and 7 days after
paclitaxel treatment. 99m Tc-EC (0.15 mg/rat, 300 𝜇Ci/rat;
𝑛 = 3) was used as a control. The images were acquired
at 1 hr, 2 hr, and 4 hr after administration of radiotracers.
Computer outlined regions of interest (ROIs in counts per
pixel) between tumor and muscle were used to calculate
tumor-to-muscle (T/M) ratios.
2.9. Statistical Analysis. Statistical analysis was performed
using Graph Pad Prism 6 software (Graph Pad, La Jolla, CA)
using ANOVA or unpaired 𝑡-test. For all tests, 𝑃 values less
than 0.05 were considered to be significant.

3.1. Growth Inhibitory Effect of Peptides A and B in Breast Cancer Lines. Inhibition of hedgehog signaling has been shown
to decrease growth and survival of breast cancer cells [2, 4].
Antibodies that disrupt the binding of sonic hedgehog to
the PTCH receptor have also been reported to inhibit breast
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Figure 2: Patched-binding peptides have significant uptake in breast cancer cell lines. (a) Fluorescence microscopy of FITC-labeled peptides A
and B in SKBR3 breast cancer cells. (b) Quantification of FITC-peptides A and B uptake in breast cancer cell lines. (c) Fluorescence microscopy
of SKBR3 cells showing colocalization of peptide B (green) with the PTCH receptor (red). Colocalization appears as yellow staining in the
image overlay.

cancer growth [5]. The PTCH-binding peptides, referred to,
in this paper, as peptides A and B, have previously been shown
to decrease hedgehog-dependent growth of pancreatic cancer
cell lines. Therefore, we sought to determine their effect on
breast cancer cell lines. As shown in Figure 1, treatment of
SkBr3 breast cancer cell lines with peptides A and B resulted
in significant growth inhibition at higher concentrations.
Minimal effect was observed at lower concentrations.

3.2. Peptide Uptake in Breast Cancer Cell Lines and Mammospheres. To validate the PTCH-binding peptides A and B as
ligands to detect breast cancer cells, we evaluated the cellular
uptake of the peptides labeled with FITC. Fluorescence
microscopy of breast cancer cell lines revealed uptake of
the FITC-tagged peptides. As shown in Figure 2(a), cytosolic
fluorescence was observed 24 hours after treatment of the
breast cancer cell line SKBR3 with peptide A or peptide B. To
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Figure 3: Uptake of patched-binding peptides is increased in mammospheres from breast cancer cell lines. (a) Fluorescence microscopy of
FITC-labeled peptides A and B in mammospheres from T47-D. (b) Quantification of FITC-peptides A and B uptake in breast cancer cell
lines in monolayer and mammosphere cultures. Uptake was significantly higher in cells cultured in mammosphere promoting conditions (3
dimensional cultures) than in those grown in standard monolayer conditions. Significance is represented by asterisk. ∗ 𝑃 ≤ 0.01.
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Figure 5: In vitro uptake of 99m Tc-EC-peptide A. Results of in vitro assays showing significant uptake of peptide A compared to 99m Tc-EC
control in (a) SUM159, (b) MDA-IBC3, and (c) 13762 breast cancer cell lines. Data is represented as % uptake per mg/protein. Error bars
represent standard deviations. Significance is represented by asterisk. ∗ 𝑃 ≤ 0.001.

quantify these findings, uptake studies were performed in a
panel of breast cancer cell lines and fluorescence intensity was
measured. As shown in Figure 2(b), significant uptake of the
fluorescent peptides was observed. Furthermore, fluorescent
intensity corresponded to PTCH expression as previously
reported [1], suggesting that binding is specific to the PTCH
receptor. To further confirm colocalization of PTCH-binding
peptides with PTCH receptor expression, we performed
fluorescence microscopy using anti-PTCH antibodies on
cells treated with FITC-labeled PTCH-binding peptides. As
shown in Figure 2(c), uptake of PTCH-binding peptides
(green) colocalized with PTCH receptor expression (red).
Hedgehog pathway members PTCH, Gli-1, and Gli-2
have been reported to be more highly expressed in normal
mammary stem cells and their malignant counterparts, breast
cancer stem cells, compared to more differentiated breast
cancer cells [6]. High expression of the PTCH receptor
has been reported in breast cancer cells cultured in stem
cell-enriching conditions (mammospheres, 3 dimensional
cultures). Consistent with these findings, an increase in

peptide uptake was observed in mammospheres compared
to 2 dimensional monolayer cultures (Figure 3). These data
indicate that PTCH-binding peptides may provide a method
of targeting breast cancer stem cells.
3.3. Synthesis and Radiolabeling of EC-Peptide A. To establish
the uptake of PTCH-binding peptides in vivo, we synthesized
chelator-peptide conjugates that could be radiolabeled with
99m
Tc for gamma scintigraphy. A simple and efficient synthesis of 99m Tc EC-PTCH was developed. EC was conjugated to
the lysine residue of peptide A. 99m Tc EC-PTCH was found
to be radiochemically pure (100%, Figure 4).
3.4. In Vitro Uptake Studies. In vitro cellular uptake of the
99m
Tc-conjugated peptide was performed in three breast
cancer cell lines: SUM159, MDA-IBC3, and 13762. As shown
in Figure 5, cellular uptake of the peptide conjugate was
significantly higher than that of the chelator alone in all lines.
Similar to the data for the FITC-tagged peptide, the SUM159
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T/M = 4.70

T/M = 3.47

T/M = 5.52

we expect that residual cells which remain after treatment
with chemotherapy would have high expression of hedgehog
pathway members. We examined PTCH expression in tumor
xenografts before and after treatment with paclitaxel. As
shown in Figure 7(a), an increase in PTCH protein expression
is observed in the residual tumor seven days after treatment.
Although there was a decrease in tumor volume after treatment, planar imaging with 99m Tc-EC-peptide A revealed no
significant decrease in tumor accumulation of the peptide
(Figure 7(b)). These findings suggest that PTCH receptor
imaging may provide a useful method to assess resistant
tumor tissue after chemotherapy treatment.

2 hr

4. Discussion

T/M = 3.51

T/M = 4.54

T/M = 4.25

T/M = 3.17

T/M = 5.40

4 hr

T/M = 4.02

Figure 6: In vivo uptake of 99m Tc-EC-peptide A in rats bearing
13762 breast carcinoma xenografts. Tumor-to-muscle (T/M) ratios
are given for 3 separate rats at multiple timepoints after injection of
the radiotracer. Arrows indicate tumor location.

line showed the highest radiotracer uptake with approximately 18% uptake per mg protein at 4 hours (Figure 5(a)).
Significant uptake of the radiotracer was also observed in two
other lines, increasing steadily in MDA-IBC3 (Figure 5(b))
and reaching saturation after 1-2 hours in 13762 (Figure 5(c)).
3.5. In Vivo Imaging. To investigate the utility of peptide
imaging of the PTCH receptor in breast cancer, planar
scintigraphy was performed in a rat model of breast cancer
using 99m Tc-EC-peptide A. Fisher rats were inoculated with
the mammary carcinoma cell line 13762, and after tumors
grew for two weeks, rats were injected with approximately
300 𝜇Ci of the 99m Tc-labeled peptide. Planar scintigraphy was
conducted at 1, 2, and 4 hours after injection of the radiolabeled peptide, and tumor-to-muscle ratios were calculated.
An average tumor-to-muscle ratio of 4.5 ± 0.07 was obtained
at 1 hour. Significant retention of the peptide was observed in
the tumor tissue up to 4 hours after injection (Figure 6).
Several studies have reported that hedgehog signaling
induces resistance to chemotherapy [4, 7, 8]. Therefore,

Neoadjuvant chemotherapy is commonly prescribed for
treatment of invasive or large tumors to allow for breastconserving surgery. However, there is currently no reliable
method to noninvasively follow response to chemotherapy. It
is unclear whether the current standard for clinical imaging,
18
F-FDG PET, is predictive of treatment response due to
false positive results following treatment. In vitro and in vivo
studies have demonstrated high FDG uptake in inflammatory
lesions [5]. Increased FDG uptake in macrophages and
neutrophils caused by treatment-induced inflammation has
also been reported [9, 10].
We show that in vivo imaging with 99m Tc-PTCH peptides may offer an alternative method to follow treatment
response and allow for tumor-specific imaging prior to and
immediately after chemotherapy treatment. Our data suggest
that peptides which bind to the ligand docking site of the
hedgehog receptor, PTCH, are localized to breast cancers in
vivo. Furthermore, we show that PTCH receptor expression
is increased after paclitaxel treatment in a rat model of
breast cancer. These results indicate that PTCH-positive,
treatment-resistant cells may be enriched after chemotherapy.
In addition to tumor uptake, significant uptake of the peptide
was observed in liver and kidney tissues. This may be due to
clearance of the peptide and the FITC tag. Additionally, liver
uptake may be due to low level endogenous expression of the
PTCH receptor by liver tissue. Although our work and that
of others [2] suggest that PTCH docking peptides specifically
target the PTCH receptor on cancer cells, binding to other cell
surface receptors cannot be ruled out.
The cancer stem cell hypothesis states that tumors consist
of a heterogeneous population of cells, including both rapidly
dividing, differentiated cells that can be effectively targeted
by chemotherapy and relatively resistant stem-like cells [11].
Previous studies have reported that breast cancer stem cells
express high levels of the PTCH receptor and that hedgehog
signaling is required for the growth of these cells [6]. Our data
indicate that PTCH-binding peptides have higher uptake in
cells cultured under stem cell-promoting conditions (mammospheres) and may serve as a ligand to detect and target this
cell population. Additionally, our findings suggest that PTCH
receptor-positive cells are resistant to chemotherapy and that
99m
Tc-peptide A may be a useful agent for the detection of
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Figure 7: PTCH expression is increased in breast cancer xenografts after chemotherapy treatment. (a) Immunohistochemical detection of
PTCH before and after treatment with paclitaxel. (b) Tumor uptake of 99m Tc-EC-peptide A is increased after treatment with chemotherapy.
Data represents % injected dose in the ROI of the tumor. Error bars represent standard deviation. Significance is represented by asterisk.
∗
𝑃 ≤ 0.05.

treatment-resistant breast cancer cells with active hedgehog
signaling.
PTCH-blocking peptides have been shown to decrease
growth of pancreatic cancer cell lines [2]. Similar to previous
studies, we show that treatment of breast cancer cell lines with
PTCH-binding peptides decreases growth of breast cancer
cell lines. While our preliminary results suggest that PTCHbinding peptides may slow growth of breast cancer, further
study is needed to validate the therapeutic effect. Our data
also indicate that further evaluation of the effect of PTCHbinding peptides on tumor detection, growth, and survival
in orthotopic models of breast cancer is warranted. These

peptides may serve as useful theranostics which may be used
to both image and treat breast cancer.
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